VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

(VINAVETCO)

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness

PROGRAMME EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS 2026 VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

+ **Time to welcome and check shareholder status**: From 7:30 to 8:00 Saturday, November 07, 2026

+ **Expected meeting time:** From 8:00 to 12:30, Saturday, November 07, 2026

+ **Address: Central Veterinary Company Limited 1**: Address: At Binh Luong Hamlet, Nhu Quynh Commune, Hung Yen Province

Time	The main contents of the meeting
I	**CONGRESS OPENING PROCEDURES**
7:30 – 8:00	- Welcoming, registering delegates and distributing documents
8:00 – 8:30	- Opening, declaring the reason, introducing delegates and guests
	- Announcing the decision to establish the Shareholder Qualification Examination Committee
	- Announcing the results of the shareholder qualification examination
	- Approving the Presidium
	- Approving the Secretariat
	- Approving the Ballot Counting Committee
	- Approving the Agenda and Regulations of the Congress
II	**REPORTS AND SUBMISSIONS**
8:30 – 9:45	- Report on the Activities of the Board of Directors of the Company for the 2022–2026 Period and Directions for the Activities of the Board of Directors for the VIII Term, 2026–2031 - Report of the Audit Committee for the 2022–2026 Period.
	CONTENTS OF THE PRESENTATION TABLES:
	1. Approval of the dismissal of Mr. Nguyen Anh Tuan and Ms. Tran Thi Bich Ngoc as members of the Board of Directors pursuant to their resignation letters dated August 17, 2026.
	2. Seeking approval from the General Meeting of Shareholders for the early termination of the Board of Directors' Term VII (2022–2027); and concurrently conducting the election of the Board of Directors and Independent Board Member(s) for Term VIII (2026–2031) at the 2026 Extraordinary General Meeting of Shareholders
	3. Approval of the Board of Directors' Activity Report for the 2022–2026 Period and the Directions for the Board of Directors' Activities for the VIIIth Term (2026–2031)
	4. Approval of the Report on the Activities of the Audit Committee for the 2022–2026 Period
	5. Other *matters*.

Time	The main contents of the meeting
III	**DISCUSS**
9:45 – 10:20	– *Shareholders participate in giving opinions, discussing and answering questions from the Presidium*
IV	**VOTING ON CONGRESS PROPOSALS**
10:20-10:35	*- Discussion and voting on the approval of the reports and proposals;* *- Approval of the Election Regulations and election guidelines;* *- Election of members of the Board of Directors and an Independent Member of the Board of Directors for the 2026–2031 term;* *- Other matters.*
V	**BREAK AND VOTE COUNTING**
10:35– 11:15	*- Shareholders take a break;* *- The Vote Counting Committee counts the ballots for the election and voting on matters at the Meeting..*
IV	**END OF CONGRESS**
11:15-12:00	*- Announcement of the Minutes of the vote counting*
	- Announcement of the voting results for the election of members of the Board of Directors and an Independent Member of the Board of Directors for the 2026–2031 term;
	- Announcement of the election results for the Chairman of the Board of Directors;
	- Approval of the Minutes and Resolution of the 2026 Extraordinary General Meeting of Shareholders.
	- Declaration of the closing of the General Meeting

VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

(VINAVETCO)

No: 43 -2026 /TTr-ĐHĐCĐBT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness

Hanoi, September 08, 2026

SUBMISSION

Re: Approval of the Dismissal of Members of the Board of Directors

TO : THE 2026 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

CENTRAL VETERINARY PRODUCTS JOINT STOCK COMPANY I

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Law amending and supplementing a number of articles of the Law on Enterprises No. 76/2025/QH15, adopted by the 15th National Assembly of the Socialist Republic of Vietnam at its 9th Session on June 17, 2025; and its guiding documents;
- Pursuant to the Charter on Organization and Operation of Central Veterinary products Joint Stock Company I;
- Pursuant to the Resignation Letter of Mr. Nguyen Anh Tuan and the Letter of Request for Cessation of Duties of Ms. Tran Thi Bich Ngoc dated August 17, 2026.

The Board of Directors respectfully submits to the Extraordinary General Meeting of Shareholders of the Company for consideration and approval the dismissal of the following members of the Board of Directors for the 2022–2027 term:

1. Mr. Nguyễn Anh Tuấn
Approval of the dismissal from the position of Member of the Board of Directors and cessation of the position of Chairman of the Board of Directors for the 2022–2027 term, pursuant to the Resignation Letter dated August 17, 2026.

2. Ms. Trần Thị Bích Ngọc
Approval of the dismissal from the position of Member of the Board of Directors for the 2022–2027 term, pursuant to the Request to Relinquish Duties dated August 17, 2026.

The Board of Directors respectfully submits the above matters to the General Meeting of Shareholders for consideration and approval.

Yours sincerely!

ON BEHALF OF THE BOARD OF DIRECTORS
Chairman of the board of directors

CÔNG TY CỔ PHẦN THUỐC THÚ Y TRUNG ƯƠNG I

Nguyen Anh Tuan

VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

(VINAVETCO)

No: 44 -2026 /TTr-ĐHĐCĐBT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness

Hanoi, September 08, 2026

SUBMISSION

Re: Early Termination of the VIIth Term (2022–2027) of the Board of Directors and Election of the Board of Directors and Independent Members of the Board of Directors for the VIIIth Term (2026–2031)

TO : THE 2026 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

CENTRAL VETERINARY PRODUCTS JOINT STOCK COMPANY I

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Law amending and supplementing a number of articles of the Law on Enterprises No. 76/2025/QH15, adopted by the 15th National Assembly of the Socialist Republic of Vietnam at its 9th Session on June 17, 2025; and its guiding documents;
- Pursuant to the Charter on Organization and Operation of Central Veterinary products Joint Stock Company I;

The Board of Directors respectfully submits to the Extraordinary General Meeting of Shareholders of the Company for consideration and approval of the following matters:

1. Approval of the early termination of the VIIth term (2022–2027) of the Company's Board of Directors.
2. Approval of the election of members of the Board of Directors and independent members of the Board of Directors for the VIIIth term (2026–2031) at the 2026 Extraordinary General Meeting of Shareholders.

The Board of Directors respectfully submits the above matters to the General Meeting of Shareholders of the Company for consideration and approval.

Yours sincerely!

ON BEHALF OF THE BOARD OF DIRECTORS
Chairman of the board of directors

CÔNG TY CỔ PHẦN THUỐC THÚ Y TRUNG ƯƠNG I

Nguyen Anh Tuan

VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

(VINAVETCO)

No: 45 -2026 /TTr-ĐHĐCĐBT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness

Hanoi, September 08, 2026

SUBMISSION

Re: Approval of the Board of Directors' Activity Report for the 2022–2026 Period and the Directions for the Board of Directors' Activities for the VIIIth Term (2026–2031)

TO : THE 2026 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

CENTRAL VETERINARY PRODUCTS JOINT STOCK COMPANY I

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;
- Pursuant to the Law amending and supplementing a number of articles of the Law on Enterprises No. 76/2025/QH15, adopted by the 15th National Assembly of the Socialist Republic of Vietnam at its 9th Session on June 17, 2025;
- Pursuant to the Charter on Organization and Operation of Central Veterinary products Joint Stock Company I;

The Board of Directors respectfully submits to the Extraordinary General Meeting of Shareholders of the Company for consideration and approval of the following matter:

1. Approval of the Report on the Activities of the Board of Directors for the 2022–2026 period.

The Board of Directors respectfully submits the above matter to the General Meeting of Shareholders of the Company for consideration and approval.

Yours sincerely!

ON BEHALF OF THE BOARD OF DIRECTORS
Chairman of the board of directors

CÔNG TY CỔ PHẦN THUỐC THÚ Y TRUNG ƯƠNG I – THÀNH PHỐ HÀ NỘI

Nguyen Anh Tuan

VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I	**SOCIALIST REPUBLIC OF VIETNAM**
(VINAVETCO)	**Independence - Freedom – Happiness**
No: 46 -2026 /TTr-ĐHĐCĐBT	Hanoi, September 08, 2026

SUBMISSION

Re: Approval of the Report on the Activities of the Audit Committee for the 2022–2026 Period

TO : THE 2026 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

CENTRAL VETERINARY PRODUCTS JOINT STOCK COMPANY I

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; and implementing documents;

- Pursuant to the Law amending and supplementing a number of articles of the Law on Enterprises No. 76/2025/QH15, adopted by the 15th National Assembly of the Socialist Republic of Vietnam at its 9th Session on June 17, 2025;

- Pursuant to the Charter on Organization and Operation of Central Veterinary products Joint Stock Company I;

The Board of Directors respectfully submits to the Extraordinary General Meeting of Shareholders of the Company for consideration and approval of the following matter:

1. Approval of the Report on the Activities of the Audit Committee for the 2022–2026 period.

The Board of Directors respectfully submits the above matter to the General Meeting of Shareholders of the Company for consideration and approval.

Yours sincerely!

ON BEHALF OF THE BOARD OF DIRECTORS
Chairman of the board of directors

CÔNG TY CỔ PHẦN THUỐC THÚ Y TRUNG ƯƠNG I

Nguyen Anh Tuan

VIETNAM VETERINARY PRODUCTS
JOINT STOCK COMPANY I

(VINAVETCO)
No.: 02-2026/BC-UBKT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

Hanoi, September 08, 2026

REPORT OF THE AUDIT COMMITTEE

Submitted to the 2026 Extraordinary General Meeting of Shareholders on the Operations of the Audit Committee for the 2022–2026 Period

Respectfully submitted to: THE GENERAL MEETING OF SHAREHOLDERS

Pursuant to the objectives and tasks set at the beginning of the term, the Audit Committee hereby reports to the 2026 Extraordinary General Meeting of Shareholders on its operating results for the 2022–2026 period as follows:

I. SUMMARY OF THE ORGANIZATION AND OPERATIONS OF THE AUDIT COMMITTEE

1. Organizational structure

Since May 28, 2022, the Company has been organized and operated under the model prescribed in Point b, Clause 1, Article 137 of the Law on Enterprises, comprising the General Meeting of Shareholders, the Board of Directors and the General Director. The Company has an Audit Committee under the Board of Directors, in accordance with the regulations approved under Resolution No. 21-2022/NQ-GMS dated May 28, 2022.

The structure and membership of the Audit Committee during the 2022–2026 period were as follows:

No.	Full Name	Position	Executive / Non-executive	Term of Office
1	Nguyễn Việt Hoàng	Chairman of the Audit Committee	Non-executive	From May 28, 2022 to present
2	Trần Thị Bích Ngọc	Member of the Audit Committee	Non-executive	From April 26, 2025 to present
3	Phan Quốc Duy	Member of the Audit Committee	Non-executive	From May 4, 2024 to April 26, 2025
4	Bùi Hương Liên	Member of the Audit Committee	Non-executive	From May 6, 2023 to May 4, 2024
5	Tô Giang Nam	Member of the Audit Committee	Non-executive	From May 28, 2022 to May 6, 2023

- The Audit Committee assigned specific tasks to each member in areas suited to their professional expertise. Members regularly exchanged information and communicated via email, telephone and direct discussion, ensuring smooth and timely communication in line with the Company's business operations.

- During the period from 2022 to present, the Audit Committee held 9 meetings on matters arising during the year and on the annual summary reports of its operations; meetings were attended in full by all members, as detailed below:

No.	Board of Directors Member	Meetings attended, 6M/2026	Meetings attended, 2025	Meetings attended, 2024	Meetings attended, 2023	Meetings attended, 2022	Attendance rate	Reason for non-attendance
1	Nguyễn Việt Hoàng	01	02	02	02	02	100%	
2	Trần Thị Bích Ngọc	01	01				100%	Appointed on April 26, 2025
3	Phan Quốc Duy		01	01			100%	Removed on April 26, 2025
4	Bùi Hương Liên			01	01		100%	Removed on May 4, 2024
5	Tô Giang Nam				01	02	100%	Removed on May 6, 2023

- Audit Committee members made every effort to attend all Board of Directors meetings in full and to remain fully informed of the Company's production and business activities.

2. Operations of the Audit Committee

During the 2022–2026 period, the Audit Committee performed its supervisory and advisory functions for the Board of Directors within its authority, focusing on:

- Supervising the truthfulness and reasonableness of financial statements and accounting work; supervising the internal control and risk management systems; supervising independent audit activities; monitoring and evaluating the implementation of recommendations made by the independent auditor and competent authorities; supervising compliance with the law, the Charter and the Company's internal regulations; and performing other duties as prescribed by law, the Charter and as assigned by the Board of Directors.

3. Remuneration and other benefits of the Audit Committee

During the 2022–2026 period, members of the Audit Committee received remuneration and other benefits in accordance with the annual resolutions of the General Meeting of Shareholders, the Company's regulations, and commensurate with their assigned functions and duties.

The payment of remuneration, salaries and other benefits to members of the Audit Committee was carried out in accordance with the Company's regulations, ensuring transparency and compliance with the law, specifically as follows:

No.	Full Name	2022	2023	2024	2025	6M/2026
1	Nguyễn Việt Hoàng	14,000,000	24,000,000	24,000,000	24,000,000	12,000,000
2	Tô Giang Nam	14,000,000	8,000,000			
3	Bùi Hương Liên		16,000,000	8,000,000		
4	Phan Quốc Duy			16,000,000	8,000,000	
5	Trần Thị Bích Ngọc				16,000,000	12,000,000
	Total	**28,000,000**	**48,000,000**	**48,000,000**	**48,000,000**	**24,000,000**

Source: The Company's audited consolidated financial statements for the relevant years, audited by UHY Auditing and Consulting Co., Ltd.

Apart from the amounts stated above, members of the Audit Committee had no other benefits from the Company that could affect their independence and objectivity in performing their supervisory function.

II. SUPERVISION RESULTS AND ASSESSMENT FOR THE 2022–2026 PERIOD

1. Preparation and disclosure of financial statements

- The Audit Committee supervised the preparation of annual and interim financial statements; assessed compliance with accounting, financial and disclosure regulations; coordinated and communicated with the independent auditor during the audit process; and monitored the resolution of issues and recommendations raised in the audit reports.

- The preparation and disclosure of financial statements were carried out by the Company in accordance with applicable regulations; issues arising during the preparation of reports were monitored, discussed and recommended for timely resolution by the Audit Committee within its authority. Annual financial statements were approved at the annual General Meetings of Shareholders each year.

2. Independent audit

- Each year, the Audit Committee evaluated the selection and proposal of the independent auditor; supervised the independence and objectivity of the audit staff working directly on the engagement; monitored the audit process of the financial statements; proactively communicated with the independent auditor on material matters arising; and monitored the implementation of audit recommendations.

- The audit firm selected (UHY Auditing and Consulting Co., Ltd.) ensured reliability, complied with deadlines and professional regulations, and maintained independence and objectivity in forming its audit opinions. The Audit Committee did not identify any conflict of interest or issue affecting the independence or objectivity of the auditors, the audit team or the audit firm during the audit process.

3. Internal control system and risk management

Internal control work was carried out effectively, with operating units following correct procedures. The Company issued and strictly implemented internal control and risk management procedures in accordance with the law. During the term, the Audit Committee focused on the following key matters:

- Assessing the status of the internal control system;

- Supervising the management of material risks in production, business and financial activities;

- Monitoring the management of payables/receivables, inventory, assets, cash flow and receivables;

- Recommending enhanced control measures for areas with residual risk exposure.

4. Financial position and material matters

- During the term, the Audit Committee focused on supervising matters of material significance to the Company's financial position and operations, including: revenue, profit and operating efficiency; receivables and their collectability; inventory and provisioning; accumulated losses carried over from previous periods; solvency and cash flow; and the management and use of

capital and assets. The key financial indicators for the 2022–2025 period and the first six months of 2026 were as follows:

Financial indicators	2022	2023	2024	2025	6M/2026	6M/2025
Net revenue	138,606,828,632	94,339,484,657	109,113,684,605	111,692,250,742	66,433,052,667	48,965,241,893
Net profit from business operations	3,816,337,913	2,588,981,277	4,274,591,547	8,470,501,184	2,998,802,311	1,254,437,154
Profit before tax	6,183,233,583	4,268,778,453	5,093,646,511	10,819,960,752	3,011,786,227	3,881,517,729
Profit after tax	5,595,254,900	3,381,284,688	3,777,670,212	8,453,238,318	2,386,922,324	3,092,085,530
Short-term payables	42,336,238,721	41,548,941,702	42,042,724,462	41,127,213,214	45,626,251,794	42,187,897,982
Profit distribution	0%	0%	0%	0%	0%	0%

Source: The Company's audited/reviewed consolidated financial statements for the relevant years, prepared by UHY Auditing and Consulting Co., Ltd.

Overall, the key financial indicators for the 2022–2025 period showed an improving trend: accumulated losses decreased from VND 71.65 billion (as at December 31, 2022) to VND 54.30 billion (as at June 30, 2026), a reduction of VND 17.35 billion (approximately 24.2%); net cash flow from operating activities also improved markedly year on year, reaching VND 10.14 billion in 2025. However, the Audit Committee notes that in the first six months of 2026, net cash flow from operating activities turned negative at VND 6.56 billion despite the Company remaining profitable, mainly due to an increase of approximately VND 7.04 billion in trade receivables and approximately VND 3.68 billion in inventory compared with the end of 2025. The Audit Committee recommends that the Board of Directors and the Executive Management closely monitor this development, and strengthen receivables collection and inventory control in the coming quarters. The Company still has certain financial issues originating from previous periods; during the 2022–2026 term, the Company focused its resources on addressing these issues and gradually stabilized its operations and improved business efficiency, although some matters have not yet been fully resolved and should continue to receive the attention of the Board of Directors and the Executive Management in the new term.

5. Supervision of legal compliance and information disclosure

- Compliance with the Law on Enterprises, the Law on Securities, the Company's Charter and other relevant regulations: the Company seriously carried out information disclosure in accordance with regulations; during this period, the Audit Committee did not note any instance of the Company being cautioned for failing to fulfill its information disclosure obligations.

- Implementation of resolutions and decisions of the General Meeting of Shareholders and the Board of Directors: the Company consistently complied with corporate governance regulations and protected shareholders' rights and interests.
- Transactions between Central Vietnam Veterinary Products Joint Stock Company I and its subsidiary and related parties of the Company were all carried out in accordance with applicable regulations. The Audit Committee did not identify any irregularities in these transactions.

III. ASSESSMENT OF THE OPERATIONS OF THE BOARD OF DIRECTORS AND THE EXECUTIVE MANAGEMENT

1. Regarding the Board of Directors

The Audit Committee assesses that, during the 2022–2026 term, the Board of Directors performed its governance, direction and supervisory functions over the Company's operations in accordance with regulations; placed emphasis on resolving issues carried over from previous periods; and gradually stabilized production and business operations while addressing financial issues.

- During the term, the Company's Board of Directors held its meetings in person. All meetings were conducted in accordance with the order and procedures prescribed in the Charter of Central Vietnam Veterinary Products Joint Stock Company I and the Law on Enterprises.

Based on the actual situation and the audited financial statements, the Audit Committee did not identify any irregularities in the Company's management and governance activities.

- The Executive Management made considerable efforts in managing the Company's production and business activities in line with the direction set by the Board of Directors.

- However, accumulated losses sustained over many previous consecutive years remained a significant financial burden for the Company. The Board of Directors and the Executive Management actively sought solutions to enhance and strengthen the Company's market position and regain market share, through the launch of new products and new product lines, continued improvement of product quality, and closer engagement with the Company's entire customer network.

- The Board of Directors set specific annual plan targets, which were submitted to and approved by the annual General Meetings of Shareholders each year.

- Notably, during the 2022–2026 period, the Board of Directors made significant efforts to implement important Resolutions/Decisions marking historic milestones for the Company, as follows:

+ The Board of Directors implemented Resolution No. 21/2022/NQ-GMS of the General Meeting of Shareholders dated May 28, 2022 on the use of share premium to address accumulated losses, which significantly improved the Company's financial position and created a foundation for the 2022–2026 period.

+ The Board of Directors implemented Resolution No. 41/2022/NQ-GMS of the General Meeting of Shareholders dated October 22, 2022 on increasing capital by VND 20 billion to construct the Beta-lactam production workshop in accordance with GMP-WHO standards; the Company invested in the construction of the workshop, which was subsequently assessed as satisfying the conditions for operation in accordance with GMP-WHO standards.

2. Regarding the Executive Management

- During the 2022–2026 period, the Executive Management seriously organized the implementation of resolutions and decisions of the General Meeting of Shareholders and the Board of Directors; proactively managed production and business activities and addressed outstanding issues; and gradually improved operating efficiency and the Company's financial position.

- The management of the Company's finances, capital and assets during the 2022–2026 period is reflected in the following key indicators:

Indicator	12/31/2022	12/31/2023	12/31/2024	12/31/2025	6/30/2026
Total assets	147,421,040,881	151,185,028,550	155,776,481,522	163,114,208,592	168,200,169,496
Total liabilities	72,735,238,721	53,367,941,702	54,381,724,462	53,466,213,214	56,165,251,794
Owners' equity	74,685,802,160	97,817,086,848	101,394,757,060	109,647,995,378	112,034,917,702
Accumulated losses	-71,652,033,319	-68,520,748,631	-64,943,078,419	-56,689,840,101	-54,302,917,777
Inventory	17,552,183,675	17,446,220,537	19,444,138,888	18,818,063,220	22,501,632,664
Trade receivables	17,264,664,490	6,690,200,055	10,252,671,297	12,077,864,752	19,118,134,418
Net cash flow from operating activities	2,448,675,509	3,973,732,295	4,036,546,977	10,135,036,515	-6,564,294,789

Source: The Company's audited/reviewed consolidated financial statements for the relevant years, prepared by UHY Auditing and Consulting Co., Ltd.

- Nevertheless, certain outstanding issues relating to receivables/payables, inventory, finance and operating efficiency still need to be further addressed.

IV. OVERALL ASSESSMENT OF THE AUDIT COMMITTEE

1. Achievements

- The Company's operations have gradually stabilized and shown positive developments; governance, financial control and information disclosure have been progressively strengthened; production and business efficiency has shown an improving trend; financial issues carried over from previous periods have been progressively identified and addressed; and coordination among the Board of Directors, the Executive Management, the Audit Committee and the independent auditor has been well maintained.

2. Remaining issues and limitations

- Certain financial and receivables/payables issues from previous periods have not yet been fully resolved; inventory and certain asset items require further review and resolution; the internal control system requires further improvement; risk management needs to be strengthened; and certain matters at operating units/branches require continued control and remediation.

V. RECOMMENDATIONS OF THE AUDIT COMMITTEE FOR THE 2026–2031 TERM

Based on its review, the Board of Directors and the Audit Committee note that the Ho Chi Minh City Branch has been operating ineffectively, with no feasible plan yet in place to resolve its outstanding issues; the previous difficulty in closing its tax code due to outstanding tax liabilities has now been resolved. On this basis, the Board of Directors and the Audit Committee jointly recommend that the Branch urgently complete the tax inspection and audit for the remaining years as a basis for closing its tax code in accordance with regulations; and that the Board of

years as a basis for closing its tax code in accordance with regulations; and that the Board of Directors and the Executive Management develop a specific plan to implement the policy of downsizing/terminating the operations of the Branch.

The Audit Committee recommends that the Board of Directors and the Executive Management of the new term focus on: fully resolving accumulated losses and financial issues carried over from previous periods; strengthening the management of receivables/payables, inventory and operating cash flow; improving internal control and risk management; enhancing the efficiency of production, business operations and capital utilization; promptly finalizing the plan for the Ho Chi Minh City Branch; fully and promptly complying with information disclosure obligations and the law; maintaining the independence and objectivity of internal/independent audit activities and of the Audit Committee; and ensuring shareholders' lawful rights and interests.

VI. CONCLUSION

During the 2022–2026 term, the Audit Committee performed its supervisory and advisory functions in accordance with the law, the Company's Charter and the Audit Committee's Operating Regulations.

The Audit Committee acknowledges the results achieved by the Company in stabilizing its operations, addressing outstanding issues and progressively improving production and business efficiency. At the same time, the Audit Committee notes that the Company still has certain matters requiring continued resolution during the 2026–2031 term, particularly outstanding financial issues, receivables/payables, inventory, the internal control system and risk management.

The Audit Committee respectfully requests that the General Meeting of Shareholders review and note the Report on the operations of the Audit Committee for the 2022–2026 period.

ON BEHALF OF THE AUDIT COMMITTEE
CHAIRMAN OF THE AUDIT COMMITTEE
(Signed and sealed)

Nguyễn Việt Hoàng

CENTRAL VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I (VINAVETCO)
No.: 42 - 2026/BC-BOD

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, September 08, 2026

REPORT OF THE BOARD OF DIRECTORS

ON THE OPERATING RESULTS FOR THE PERIOD 2022–2026 AND ORIENTATION FOR THE VIII TERM (2026–2031)

(Submitted to the 2026 Extraordinary General Meeting of Shareholders)

CENTRAL VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

Dear General Meeting of Shareholders,

First of all, on behalf of the Board of Directors, I would like to express our sincere appreciation to all shareholders for your continued support, cooperation and facilitation, which have enabled the Board of Directors and the Executive Management to carry out the objectives and tasks assigned by the General Meeting of Shareholders over the past period.

Dear Shareholders,

Pursuant to the Charter of Organization and Operation of Central Vietnam Veterinary Products Joint Stock Company I, the resolutions of the General Meeting of Shareholders and applicable laws and regulations, the Board of Directors has performed its functions, duties and powers in accordance with applicable regulations; at the same time, it has directed, supervised and coordinated with the Executive Management in managing and operating the Company's production and business activities.

The Board of Directors for the 2022–2027 term was elected by the General Meeting of Shareholders in accordance with regulations. However, pursuant to the matters submitted to the 2026 Extraordinary General Meeting of Shareholders, the Company is carrying out the early termination of the 2022–2027 term of the Board of Directors and conducting the election of the Board of Directors for the 2026–2031 term.

Accordingly, the Board of Directors hereby reports to the General Meeting of Shareholders on the activities and performance of its functions and duties during the 2022–2027 term, with a focus on the results achieved from 2022 to June 30, 2026. The Report also updates key activities and material matters undertaken by the Board of Directors from July 1, 2026 to the date of the General Meeting.

The financial data presented in this Report are compiled based on the Company's financial statements for the years 2022–2025 and the interim financial statements as at June 30, 2026, which were audited/reviewed in accordance with regulations by UHY.

On behalf of the Board of Directors, I respectfully submit to the General Meeting of Shareholders for consideration the Report on the activities of the Board of Directors for the 2022–2027 term, with the following principal contents:

PART I. OVERVIEW OF THE COMPANY'S OPERATIONS DURING THE PERIOD 2022–2026

1. General characteristics

During the period 2022–2026, Central Vietnam Veterinary Products Joint Stock Company I (the "Company") primarily engaged in the manufacture, trading and contract manufacturing of veterinary medicines and aquatic veterinary medicines; import and trading of vaccines, biological products and other products within its registered business lines.

The Company operates in the veterinary pharmaceutical manufacturing and trading sector, which is particularly affected by livestock and aquaculture conditions, disease outbreaks among livestock, poultry and aquatic species, fluctuations in input material prices, market competition, and specialized regulations governing the manufacture, trading and management of veterinary medicines.

In terms of corporate governance, the Company is organized and operates under the model prescribed in Point b, Clause 1, Article 137 of the Law on Enterprises, comprising the General Meeting of Shareholders, the Board of Directors and the General Director. The Company has an Audit Committee under the Board of Directors in accordance with applicable regulations.

During the 2022–2027 term, the Board of Directors consisted of the following members:

No.	Full Name	Position	Executive / Non-executive	Term of Office
1	Nguyễn Anh Tuấn	Chairman of the Board of Directors	Executive	From May 28, 2022 to present
2	Nguyễn Việt Hoàng	Independent Member of the Board of Directors	Non-executive	From May 28, 2022 to present
3	Trần Thị Bích Ngọc	Member of the Board of Directors	Non-executive	From April 26, 2025 to present
4	Phan Quốc Duy	Member of the Board of Directors	Non-executive	From May 4, 2024 to April 26, 2025
5	Bùi Hương Liên	Member of the Board of Directors	Non-executive	From May 6, 2023 to May 4, 2024
6	Tô Giang Nam	Member of the Board of Directors	Non-executive	From May 28, 2022 to May 6, 2023

The Board of Directors supervised the activities of the Executive Management, reviewed and decided on matters within its authority, and directed and guided the Executive Management in implementing the production and business objectives, tasks and plans approved by the General Meeting of Shareholders.

The General Director is responsible for organizing and managing the Company's day-to-day production and business activities in accordance with the law, the Company's Charter and decisions of the Board of Directors.

1.1. Organizational structure and Company units

The Company's organizational structure and operating network during the period 2022–2026 included:

- Head Office: No. 88 Truong Chinh Street, Kim Lien Ward, Hanoi, Vietnam.

- Ho Chi Minh City Branch of Central Vietnam Veterinary Products Joint Stock Company I: No. 40 Lam Thi Ho Street, Trung My Tay Ward, Ho Chi Minh City, Vietnam.
- List of subsidiaries: The Company only invests in Central Veterinary Company Limited 1, headquartered at Binh Luong Hamlet, Nhu Quynh Commune, Hung Yen Province. The principal activities of this subsidiary are the production and trading of veterinary medicines and vaccine distribution. At the end of the accounting period, the Company holds 100% of the charter capital in the subsidiary; the voting rights and economic interests are equivalent to its ownership interest.

During its operations, the Company gradually maintained and strengthened its organizational, production and business systems; at the same time, it implemented the allocation of functions and responsibilities among the Board of Directors, the Executive Management, professional departments and affiliated units to ensure that the Company's operations were conducted within the proper authority and in compliance with applicable regulations.

The Board of Directors performs governance and supervisory functions; the General Director organizes and manages day-to-day production and business activities; the Chief Accountant and professional departments perform their respective functions and duties in accordance with the Company's assignments and regulations.

1.2. Capital and shares as at the reporting date

As at the reporting date, the Company's charter capital and shares were as follows:

- **Charter capital:** VND 162,499,690,000.
- **Total issued shares:** 16,249,969 shares, including 16,249,956 outstanding ordinary shares and 13 treasury shares.

According to the shareholder list established in accordance with applicable regulations for participation in the 2026 Extraordinary General Meeting of Shareholders, the Company has [.....] shareholders entitled to attend the General Meeting.

1.3. Shareholder relations and information disclosure

During the period 2022–2026, the Company conducted corporate governance and shareholder relations in accordance with the Law on Enterprises, the Law on Securities, the Company's Charter and other relevant laws and regulations.

The Company carried out information disclosure in accordance with regulations applicable to public companies and organizations whose shares are registered for trading on the securities market. Information subject to disclosure was disclosed through the prescribed information disclosure system and posted on the Company's website.

The Company maintained the provision of information to shareholders and investors through its website, the person in charge of information disclosure and other appropriate information channels; at the same time, it received, processed and responded to requests from shareholders and investors in accordance with applicable regulations.

Through maintaining information disclosure and shareholder relations activities, the Company gradually enhanced transparency in corporate governance and management, ensured the lawful rights and interests of shareholders, and contributed to strengthening shareholders' confidence in and support for the Company's operations.

2. Production, business and market situation during the period 2022–2026

During the period 2022–2026, Central Vietnam Veterinary Products Joint Stock Company I maintained its production and business activities in veterinary medicines, aquatic veterinary medicines, vaccines, biological products and related products within its registered business lines.

Production and business activities were conducted through the Head Office and TW1 Veterinary Products Company Limited, the Company's wholly owned subsidiary. With respect to the Ho Chi Minh City Branch, due to certain difficulties and outstanding issues that had not been fully resolved during this period, its market development and business performance did not achieve the expected results.

Production and business activities were generally maintained continuously, focusing on product groups serving livestock, veterinary and aquaculture sectors. The Company also undertook contract manufacturing, importation and trading of vaccines, biological products and related products in order to diversify its product portfolio, meet customer demand and improve operational efficiency.

The Company focused on maintaining production capacity, quality control, cost management, inventory management and receivables management.

The Company's markets primarily comprise livestock, veterinary and aquaculture sectors, served through its customer, agent and distribution networks. The Company continued to maintain traditional products with established markets and brand recognition, while gradually researching, improving and supplementing its product portfolio to meet market demand and enhance competitiveness.

During 2022–2026, the Company's production and business activities were affected by various factors, including economic developments, market demand in livestock and aquaculture, animal disease outbreaks, fluctuations in input material prices, industry competition and compliance requirements under specialized regulations.

Against this backdrop, the Company gradually stabilized its production, business activities and workforce, maintained its markets, made efforts to preserve and improve sales, and implemented solutions to enhance operational efficiency and strengthen the foundation for the next development period.

2.1. Revenue and profit

During the period 2022–2026, the Company's revenue and profit fluctuated from year to year, affected by market developments, sales volume, selling prices, input material prices, production and business expenses, financial expenses and provisions recognized in accordance with regulations.

Against the backdrop of continued difficulties in production and business activities, the Company gradually stabilized its operations, maintained its market presence and made efforts to preserve and improve sales. The Company's business performance gradually improved during this period, contributing to the continuity of operations and establishing a foundation for development in the subsequent period.

In addition, the Company continued to address financial difficulties and accumulated losses arising from previous periods. The Board of Directors proactively sought solutions to strengthen capital resources, improve financial capacity and support production and business activities; at the same time, it submitted relevant policies and proposals to the General Meeting of Shareholders for consideration and approval and was assigned to organize their implementation. These solutions have initially contributed to improving the Company's financial position and creating conditions for continued operational stability.

Business results for 2022–2025 and the first six months of 2026

Unit: VND

Financial indicators	2022	2023	2024	2025	6M/2026	Total	6M/2025
1. Net revenue	138,606,828,632	94,339,484,657	109,113,684,605	111,692,250,742	66,433,052,667	520,185,301,303	48,965,241,893
2. Cost of goods sold	111,366,576,494	70,890,591,630	81,890,664,520	83,160,534,292	54,608,548,400	401,916,915,336	37,911,044,982
3. Gross profit	**27,240,252,138**	**23,448,893,027**	**27,223,020,085**	**28,531,716,450**	**11,824,504,267**	**118,268,385,967**	**11,054,196,911**
4. Financial income	753,994,212	546,117,635	588,623,333	599,205,099	667,168,543	3,155,108,822	244,459,058
5. Financial expenses	1,996,206,383	666,642,094	851,079,637	659,506,865	215,395,051	4,388,830,030	446,894,705
6. Selling expenses	12,845,514,597	11,767,874,117	12,814,330,333	10,161,234,236	4,365,730,991	51,954,684,274	4,898,338,957
7. General and administrative expenses	9,336,187,457	8,971,513,174	9,871,641,901	9,839,679,264	4,911,744,457	42,930,766,253	4,698,985,153
8. Profit from production and business activities	**3,816,337,913**	**2,588,981,277**	**4,274,591,547**	**8,470,501,184**	**2,998,802,311**	**22,149,214,232**	**1,254,437,154**
9. Other profit	2,366,895,670	1,679,797,176	819,054,964	2,349,459,568	12,983,916	7,228,191,294	2,627,080,575
10. Profit before tax	**6,183,233,583**	**4,268,778,453**	**5,093,646,511**	**10,819,960,752**	**3,011,786,227**	**29,377,405,526**	**3,881,517,729**
11. Current corporate income tax	587,978,683	887,493,765	1,315,976,299	2,366,722,434	624,863,903	5,783,035,084	789,432,199
12. Profit after corporate income tax	**5,595,254,900**	**3,381,284,688**	**3,777,670,212**	**8,453,238,318**	**2,386,922,324**	**23,594,370,442**	**3,092,085,530**
13. Basic earnings per share (VND)	393	211	220	520	66	1,410	36

Source: The Company's audited consolidated financial statements for the relevant years audited by UHY.

Based on the above data, the Company's production and business activities during 2022–2026 showed a recovery and improvement in operational efficiency, specifically:

- **Revenue:** Revenue declined sharply in 2023, down 31.94% to VND 94.34 billion; it then recovered gradually in 2024 (+15.66%) and 2025 (+2.36%). However, 2025 revenue (VND 111.69 billion) represented only approximately 80.6% of the 2022 level (VND 138.61 billion), indicating that the Company has not yet fully recovered its revenue scale from the beginning of the term despite the positive growth trend.

- **Gross profit margin:** Gross profit margin improved markedly year on year, from 19.65% (2022) to 24.86% (2023), 24.95% (2024) and 25.54% (2025), reflecting better cost-of-goods and product-mix management; however, it declined to 17.80% in the first six months of 2026, a matter requiring continued attention (see below).

- **Profit from production and business activities:** Profit from production and business activities reached VND 8.47 billion in 2025, up 98.16% compared with 2024 (VND 4.27 billion); the ratio of operating profit to revenue increased from 3.92% (2024) to 7.58% (2025), reflecting a genuine improvement in core operating efficiency rather than revenue growth alone.

- **Other profit:** Other profit represented a significant proportion of profit before tax in most years (38.28% in 2022, 39.35% in 2023, 16.08% in 2024 and 21.71% in 2025), whereas it accounted for only 0.43% in the first six months of 2026, meaning that profit in that period was derived almost entirely from core production and business activities. As other profit is typically non-recurring in nature, in assessing the quality of earnings for the term the Board of Directors considers it important to emphasize the sustainable contribution from core business operations, so as to avoid giving shareholders the impression that the entire increase in 2025 profit stemmed from core production and business activities.

- **Profit before tax:** Profit before tax reached VND 10,819,960,752 in 2025, up 112.41% compared with 2024 (VND 5.09 billion), the highest annual result for the period 2022–2025.

- **Profit after tax:** Profit after tax reached VND 8.45 billion in 2025, up 123.77% compared with 2024; the ratio of profit after tax to revenue increased from 3.46% (2024) to 7.57% (2025). Notably, profit after tax in 2025 exceeded the 2022 level (VND 5.6 billion) by approximately 51%, even though 2025 revenue remained lower than in 2022, indicating a significant improvement in profitability per unit of revenue compared with the beginning of the term.

- **Basic earnings per share (EPS):** EPS increased from VND 220 (2024) to VND 520 (2025); in the first six months of 2026, it reached VND 66. Due to the seasonal nature of the industry, six-month EPS does not fully reflect the expected results for full-year 2026.

- **Summary for 2022–2025:** The Company overcame the difficulties experienced in 2023, gradually recovered from 2024 and achieved its best results in 2025, with profit after tax up 123.77% compared with 2024.

- **First six months of 2026:** Revenue reached VND 66.43 billion, up 35.67% compared with the same period in 2025; however, profit after tax was VND 2.39 billion, down 22.81% year on year, and gross profit margin declined to 17.80% from 25.54% in 2025 — matters requiring continued monitoring and remedial measures in the remaining months of the year.

2.2. Financial position, receivables, inventories, capital and cash flows

Central Vietnam Veterinary Products Joint Stock Company I reports on its financial position at the beginning of the period and the solutions implemented as follows:

As at December 31, 2021, immediately preceding the reporting period, the Company's accumulated losses amounted to VND 192,367,273,123, exceeding contributed owners' capital by VND 49,867,583,123. Current liabilities also exceeded current assets by VND 21,828,885,834.

In response to this situation, the Company submitted, and the General Meeting of Shareholders approved, a plan to use share premium of VND 115,119,984,904 to offset part of the accumulated losses, while restructuring short-term and long-term borrowings.

In 2021, the Board of Directors implemented the resolutions of the Extraordinary General Meeting of Shareholders regarding the issuance of shares to strategic investors and professional securities investors and the issuance of debt-to-equity swap shares. As a result, the Company fully repaid borrowings raised from individuals and organizations, reduced outstanding debt obligations and increased share premium by VND 115.12 billion, thereby significantly improving the Company's financial position compared with 2020 and creating a foundation for the 2022–2026 period.

To meet capital requirements for investment in production and business activities, market development, and repair of the factory, machinery and equipment in 2022 and subsequent years, the Company implemented an increase in charter capital pursuant to Resolution No. 46/2021/NQ-GMS dated December 11, 2021 of the Annual General Meeting of Shareholders. The purpose was to invest in construction of the Beta-lactam Plant and repair and upgrade existing factories, machinery and equipment. The expected increase in charter capital was VND 20 billion through a private placement to shareholders, employees and investors experienced in the veterinary pharmaceutical sector.

During 2022–2026, the Company's financial position was affected by the scale of production and business activities, working capital requirements, receivables, inventories and cash flow balancing capacity.

- **Inventories:** The Company regularly reviewed the condition, recoverability and net realizable value of goods, raw materials and finished products; and processed, liquidated or made provisions for damaged, slow-moving or potentially unrecoverable inventories.

- **Trade receivables:** The Company strengthened the monitoring, reconciliation and collection of receivables and classified receivables by maturity and recoverability to determine appropriate measures.

- **Cash flows:** The Company focused on balancing capital resources for production and business activities, prioritizing working capital, settlement of due obligations and maintenance of regular operations.

Key financial indicators for 2022–2026:

Unit: VND

Indicator	31/12/2022	31/12/2023	31/12/2024	31/12/2025	30/6/2026
Total assets	147,421,040,881	151,185,028,550	155,776,481,522	163,114,208,592	168,200,169,496
Liabilities	72,735,238,721	53,367,941,702	54,381,724,462	53,466,213,214	56,165,251,794
Equity	74,685,802,160	97,817,086,848	101,394,757,060	109,647,995,378	112,034,917,702
Accumulated losses	-71,652,033,319	-68,520,748,631	-64,943,078,419	-56,689,840,101	-54,302,917,777
Inventories	17,552,183,675	17,446,220,537	19,444,138,888	18,818,063,220	22,501,632,664
Trade receivables	17,264,664,490	6,690,200,055	10,252,671,297	12,077,864,752	19,118,134,418
Net cash flows from operating activities	2,448,675,509	3,973,732,295	4,036,546,977	10,135,036,515	-6,564,294,789

Source: The Company's audited consolidated financial statements for the relevant years audited by UHY.

The above data indicate that during 2022–2026, the Company's financial position improved in a positive direction. Total assets increased from VND 147.04 billion as at December 31, 2022 to VND 168.20 billion as at June 30, 2026, while liabilities were relatively well controlled and significantly lower than at the beginning of the period.

Equity increased from VND 74.69 billion to VND 112.03 billion, contributing to the strengthening of the Company's financial foundation. In particular, accumulated losses were gradually reduced from VND 71.65 billion as at December 31, 2022 to VND 54.30 billion as at June 30, 2026. Compared with accumulated losses of VND 192.37 billion as at December 31, 2021, this represents a significant improvement.

Net cash flows from operating activities improved during 2022–2025, reaching VND 10.14 billion in 2025.

However, during the first six months of 2026, net cash flows from operating activities were negative VND 6.56 billion, while inventories and trade receivables increased. Accordingly, the Company needs to further strengthen inventory and receivables management and cash flow balancing.

Overall, during 2022–2026, the Company gradually improved its financial capacity, reduced debt pressure and narrowed accumulated losses, thereby establishing a foundation for continued stabilization and development of production and business activities in the next period.

2.3. Investment, renovation and upgrading of facilities and production capacity

During 2022–2026, the Company gradually invested in, repaired, renovated and upgraded its facilities and equipment in order to maintain and enhance production capacity, meet product quality requirements and comply with specialized regulations.

During this period, securing investment capital was one of the Company's greatest challenges. In response, the Board of Directors implemented Resolution No. 41-2022/NQ-GMS dated October 22, 2022 of the Extraordinary General Meeting of Shareholders and successfully carried out a private placement of shares to finance the construction of the Beta-lactam production workshop and related technical facilities.

On that basis, the Company promoted the development of Beta-lactam products to expand the market and contribute to maintaining stable production and business revenue.

Investment, renovation and upgrading of facilities were considered based on actual needs, available funding, product quality requirements, production conditions and investment efficiency.

Overall, during 2022–2026, the Company maintained its production and business activities, gradually strengthened production capacity and its distribution system, and implemented solutions to improve operational efficiency, financial management, receivables management and inventory management. In addition to the achievements attained, certain issues and limitations remain to be addressed and improved in the coming period.

3. Advantages, difficulties and factors affecting the Company's operations

3.1. Advantages

- The Company has more than 50 years of history and development, with its origins dating back to 1973. It is a long-established and reputable enterprise in Vietnam's veterinary pharmaceutical sector, with experience in the manufacture, trading and importation of veterinary medicines and vaccines serving the livestock industry. The Company has a diversified product portfolio, including many traditional products trusted by the market. The Company has previously had 10 products awarded the Golden Rice Ear Award and 2 products awarded Gold Medals at international trade fairs, demonstrating the quality and reputation of its products. With a nationwide customer and market network, the Company has a favorable foundation for maintaining and developing its business. In addition, the Company operates a veterinary pharmaceutical manufacturing plant meeting GMP-WHO standards and has experience in research, development and expansion of its product portfolio in response to market demand.

- To support the production of standardized and technically compliant veterinary antibiotics, the Board of Directors implemented Resolution No. 41/2022/NQ-GMS dated October 22, 2022 of the General Meeting of Shareholders on increasing capital by VND 20 billion to construct a

Beta-lactam production workshop in accordance with GMP-WHO standards. The Company invested in construction and the workshop was assessed as satisfying the conditions for operation under GMP-WHO standards, thereby improving production capacity and increasing production autonomy. With current charter capital of VND 162.5 billion, the Company has a foundation to maintain operations and continue developing in the veterinary pharmaceutical sector.

- The Company's financial position improved significantly compared with the period before 2022 as a result of using share premium to offset accumulated losses and restructuring borrowings. As at December 31, 2021, before entering the reporting period, the Company had accumulated losses of VND 192.37 billion, exceeding contributed owners' capital by VND 49.87 billion (contributed capital of VND 142.499 billion), while current liabilities exceeded current assets by VND 21.83 billion. In response, the General Meeting of Shareholders approved the use of VND 115.12 billion of share premium to offset part of the accumulated losses and restructure borrowings. In 2021, the Board of Directors implemented share issuances to strategic investors, professional securities investors and debt-to-equity swap share issuances. As a result, the Company settled borrowings raised from individuals and organizations, significantly reduced debt obligations and increased share premium by VND 115.12 billion, contributing to the improvement of its financial position and creating a foundation for the Company's operations during 2022–2026.

- The Company has the advantage of a stable and experienced workforce, particularly a team of long-serving technicians with extensive knowledge of production processes and the specific characteristics of veterinary pharmaceutical products. In addition, the Company has an experienced sales team with strong market knowledge, sales capabilities and the ability to maintain and develop customer relationships, contributing positively to market expansion and improvement of the Company's production and business results. The combination of technical expertise, production capabilities and an experienced sales force has provided an important foundation for maintaining product quality, strengthening the market position and gradually improving business performance over the years.

3.2. Difficulties

- In recent years, diseases have remained the greatest challenge facing the livestock industry, particularly African swine fever, which continues to exist. As a result, enterprises engaged in veterinary medicines and vaccines have also been significantly affected. If economic conditions develop unfavorably, the operations, revenue and profitability of companies in the sector may also be adversely affected. Therefore, the Company needs to continue assessing the impact of these factors on its production and business activities.

- The Company continues to focus on addressing accumulated losses from previous years and balancing capital resources for investment and production expansion. As at June 30, 2026, accumulated losses amounted to VND 54.3 billion. Going forward, the Company needs to continue implementing solutions to improve operational efficiency, enhance financial performance and gradually reduce accumulated losses.

- As a manufacturing enterprise, fluctuations in the prices of input materials have a significant impact on the Company's production and business activities. Recently, the prices of key raw

materials have tended to increase significantly. At the same time, the Company's working capital remains limited, which may make it difficult to mitigate the impact of raw material price fluctuations on production and business activities.

- During the past period, the Board of Directors focused most of its resources on addressing outstanding issues, stabilizing operations and gradually restoring business efficiency at the Head Office. At the Branch, certain outstanding issues have been addressed and operations have gradually become more stable; however, they have not been comprehensively resolved, and operating efficiency has not yet been commensurate with the resources required to maintain the Branch.

- The Ho Chi Minh City Branch continues to have certain outstanding issues that have not been fully resolved, and market development in the southern region has not achieved the expected results. The main reason is the unresolved issues in the management and administration of the Branch inherited from previous periods, which require time and resources for review and resolution.

- Based on the above assessment, the Board of Directors intends to consider downsizing or terminating the operations of the Ho Chi Minh City Branch in order to streamline the organizational structure, reduce operating costs and concentrate resources on production and business activities at the Head Office. At the same time, the Company will develop a plan to maintain and develop the southern market through agents, distributors or a dedicated regional sales team, ensuring continuity of product supply to customers in the region. The Board of Directors will assign the Executive Management to develop a specific plan, complete all procedures in accordance with applicable laws and submit the plan to the competent authority for consideration and decision.

4. Implementation of objectives and orientations assigned by the General Meeting of Shareholders

Comparison of annual production and business plans approved by the General Meeting of Shareholders during the term with actual results:

Unit: VND

Indicator	2022 Plan / Actual	2023 Plan / Actual	2024 Plan / Actual	2025 Plan / Actual	2026 Plan / 6M Actual
Net revenue	200,000,000,000/ 138,606,828,632	140,000,000,000/ 94,339,484,657	110,000,000,000/ 109,113,684,605	124,200,000,000/ 111,692,250,742	125,000,000,000 /66,433,052,667
Profit after tax	12,000,000,000/ 5,595,254,900	7,000,000,000/ 3,381,284,688	5,000,000,000/ 3,777,670,212	5,100,000,000/ 8,453,238,318	8,500,000,000/ 2,386,922,324
Dividend payout ratio	0	0	0	0	0
Revenue achievement ratio	69.30%	67.39%	99.19%	89.93%	53.15%
Profit after tax achievement ratio	46.63%	48.30%	75.55%	165.75%	28.08%

Source: The Company's audited consolidated financial statements for the relevant years audited by UHY.

Assessment of the implementation of objectives and orientations assigned by the General Meeting of Shareholders

During 2022–2026, the Company's production and business results fluctuated; however, overall, production and business activities were gradually stabilized and business efficiency showed an improving trend.

Regarding revenue, the Company achieved VND 138.61 billion in 2022, equivalent to 69.30% of the plan, and VND 94.34 billion in 2023, equivalent to 67.39% of the plan. From 2024, revenue recovered to VND 109.11 billion, equivalent to 99.19% of the plan, and reached VND 111.69 billion in 2025, equivalent to 89.93% of the plan.

In the first six months of 2026, revenue reached VND 66.43 billion, equivalent to 53.15% of the full-year plan. These results demonstrate that the Company has gradually overcome difficulties, stabilized production and business activities and maintained annual revenue above VND 100 billion in recent years.

Regarding profit after tax, business efficiency improved significantly. In 2022 and 2023, profit after tax reached VND 5.60 billion and VND 3.38 billion, equivalent to 46.63% and 48.30% of the respective plans. In 2024, profit reached VND 3.78 billion, equivalent to 75.55% of the plan. Notably, in 2025, profit after tax reached VND 8.45 billion, exceeding the plan approved by the General Meeting of Shareholders by 65.75%.

In the first six months of 2026, profit after tax reached VND 2.39 billion, equivalent to 28.08% of the full-year plan. This represents performance in the first half of the year, and the Company continues to focus on solutions to achieve the annual plan.

Overall, although certain revenue targets were not achieved, business efficiency showed positive improvements, particularly in 2025. This result reflects the efforts of the Board of Directors and the Executive Management in stabilizing operations, improving production and business efficiency, controlling costs and gradually restoring the Company's financial capacity.

Regarding dividend policy, during 2022–2026, the Company did not pay dividends. The primary reason was that the Company continued to have negative equity and outstanding financial matters requiring further resolution and therefore did not have sufficient conditions to distribute profits to shareholders.

The Company prioritized the use of financial resources to address outstanding issues, strengthen production and business operations, gradually improve its financial position and restore operational capacity.

PART II. SUPERVISION OF THE COMPANY'S EXECUTIVE MANAGEMENT DURING THE PERIOD 2022–2026

1. Results of supervision of the Director/Executive Management

During the period 2022–2026, the Board of Directors performed its governance, strategic direction and supervisory functions over the Director/Executive Management through Board meetings, periodic review of reports, production and business performance reports, financial reports and matters arising during operations.

The Board of Directors regularly directed and required the Executive Management to closely follow the resolutions of the General Meeting of Shareholders and the resolutions/decisions of the Board of Directors, proactively implement solutions to stabilize production and business activities, control costs, manage receivables and inventories, and balance cash flows.
In the context of the Company's outstanding financial matters and governance issues inherited from previous periods, the Executive Management coordinated with the Board of Directors to focus resources on stabilizing operations at the Head Office, maintaining production and business activities, and gradually improving revenue and operating efficiency.
The results show that production and business activities gradually recovered. In particular, profit after tax in 2025 reached VND 8.45 billion, an increase of 123.77% compared with 2024. In the first six months of 2026, revenue continued to increase by 35.67% year on year, although gross profit margin and profit after tax declined, indicating that the Executive Management needs to continue focusing on improving the quality of growth in the coming period.

2. Implementation of resolutions and decisions of the Board of Directors

The Board of Directors regularly directed and supervised the Executive Management in organizing and implementing resolutions of the General Meeting of Shareholders and the Board of Directors, focusing on key matters including:
- Implementing solutions to address accumulated losses, restructuring capital sources and gradually improving the Company's financial position;
- Implementing the investment and construction plan and putting the Beta-lactam production workshop meeting GMP-WHO standards into operation;
- Maintaining and developing production and business activities, markets and the customer network;
- Strengthening management of receivables, inventories, costs and cash flows;
- Implementing tasks relating to organizational structure, human resources, information disclosure and corporate governance.

Through its supervisory activities, the Board of Directors found that the Executive Management had implemented key matters in accordance with the directions and requirements of the Board of Directors; matters arising during operations were reported, discussed and handled in a timely manner within the relevant authority.

3. Implementation of the production and business plan

The Board of Directors regularly monitored the implementation of the production and business plan and required the Executive Management to proactively adjust solutions in response to market developments.
During 2022–2025, revenue fluctuated but recovered from 2024. In 2025, revenue reached VND 111.69 billion and profit after tax reached VND 8.45 billion, exceeding the profit plan assigned by the General Meeting of Shareholders by 65.75%.
In the first six months of 2026, revenue reached VND 66.43 billion, equivalent to 53.15% of the annual plan and up 35.67% year on year; profit after tax reached VND 2.39 billion, equivalent to 28.08% of the annual plan. These results show that revenue continued to grow, while profitability needs to be further improved during the remaining months of the year.
The Board of Directors assesses that the Executive Management made significant efforts to maintain operations, recover sales, control costs and improve business efficiency, while requiring continued focus on the quality of growth, profit margins and capital utilization efficiency.

4. Management of finance, capital and assets

The Board of Directors supervised the management of finance, capital and assets through review of financial statements, receivables, inventories, cash flows and other material financial matters of the Company.

During the term, the Company's financial position improved positively: total assets increased from VND 147.42 billion at the end of 2022 to VND 168.20 billion as at June 30, 2026; equity increased from VND 74.69 billion to VND 112.03 billion; and accumulated losses decreased from VND 71.65 billion to VND 54.30 billion.

The Board of Directors directed the Executive Management to strengthen receivables control, review and process inventories, reduce costs, balance working capital and ensure cash flows for production and business activities.

However, during the first six months of 2026, net cash flows from operating activities were negative VND 6.56 billion, while inventories and trade receivables increased. These are matters that the Board of Directors requires the Executive Management to continue focusing on and addressing.

5. Risk management and legal compliance

The Board of Directors supervised the Executive Management's compliance with laws, the Company's Charter, specialized regulations and obligations applicable to public companies, with particular attention to information disclosure, financial and accounting management, production quality standards and legal requirements applicable to the veterinary pharmaceutical sector.

The Board of Directors also required the Executive Management to proactively identify risks arising from market fluctuations, animal diseases, raw material prices, receivables, inventories, cash flows and industry competition in order to implement appropriate preventive and corrective measures.

Overall, the Company maintained its operations and complied with corporate governance, information disclosure and other regulatory obligations; matters arising were reviewed and addressed by the Board of Directors and the Executive Management within their respective authority.

6. Overall assessment of the Executive Management's activities

The Board of Directors assesses that during the term, the Executive Management made significant efforts despite the Company's financial, market and governance difficulties inherited from previous periods.

The Executive Management coordinated with the Board of Directors to focus resources on stabilizing operations at the Head Office, maintaining production and business activities, gradually recovering revenue, improving business efficiency and reducing accumulated losses. The stable and experienced technical workforce and experienced sales personnel with strong sales capabilities were positive factors supporting the Company's recovery.

In addition to the achievements attained, the Executive Management needs to continue improving management efficiency, controlling costs, receivables, inventories and cash flows; at the same time, it needs to comprehensively address outstanding issues at the Ho Chi Minh City Branch and improve the efficiency of resource utilization.

Overall, the Board of Directors recognizes the sense of responsibility and efforts of the Executive Management in maintaining operations, overcoming difficulties and gradually improving production and business performance during the term.

PART III. ACTIVITIES OF THE BOARD OF DIRECTORS AND REMUNERATION, EXPENSES AND OTHER BENEFITS OF MEMBERS OF THE BOARD OF DIRECTORS DURING THE PERIOD 2022–2026

1. Number of Board meetings during the term and attendance of each Board member

No.	Board Member	6M/2026 Meetings Attended	2025 Meetings Attended	2024 Meetings Attended	2023 Meetings Attended	2022 Meetings Attended	Attendance Rate	Reason for Non-attendance
1	Nguyễn Anh Tuấn	06	08	06	06	11	100%	Appointed on May 28, 2022
2	Nguyễn Việt Hoàng	06	08	06	06	08	100%	Appointed on May 28, 2022
3	Trần Thị Bích Ngọc	06	05				100%	Appointed on April 26, 2025
4	Phan Quốc Duy		03	03			100%	Relieved from office on April 26, 2025
5	Bùi Hương Liên			03	02		100%	Relieved from office on May 4, 2024
6	Tô Giang Nam				04	08	100%	Relieved from office on May 6, 2023

2. Key resolutions and decisions implemented by the Board of Directors during 2022–2026

During the period 2022–2026, the Board of Directors made efforts to implement important resolutions and decisions, marking notable milestones for the Company, including:

- Implementing Resolution No. 21/2022/NQ-GMS dated May 28, 2022 of the General Meeting of Shareholders regarding the use of share premium to address accumulated losses, significantly improving the Company's financial position and creating a foundation for the 2022–2026 period (see Section 2.2 of Part I);
- Implementing Resolution No. 41/2022/NQ-GMS dated October 22, 2022 of the General Meeting of Shareholders regarding the increase of capital by VND 20 billion to construct the Beta-lactam production workshop in accordance with GMP-WHO standards; the Company invested in the construction of the workshop, which was subsequently assessed as satisfying the conditions for operation (see Section 2.3 of Part I).

3. Remuneration of the Board of Directors

The Company fully paid and settled remuneration for members of the Board of Directors in accordance with the resolutions of the Annual General Meeting of Shareholders for each year, as follows:

Unit: VND

No.	Full Name	2022	2023	2024	2025	6M/2026
1	Nguyễn Anh Tuấn	36,000,000	36,000,000	36,000,000	36,000,000	18,000,000
2	Nguyễn Việt Hoàng	14,000,000	24,000,000	24,000,000	24,000,000	12,000,000
3	Tô Giang Nam	14,000,000	8,000,000			
4	Bùi Hương Liên		16,000,000	8,000,000		
5	Phan Quốc Duy			16,000,000	8,000,000	
6	Trần Thị Bích Ngọc				16,000,000	12,000,000
	Total	**84,000,000**	**84,000,000**	**84,000,000**	**84,000,000**	**42,000,000**

4. Operating expenses of the Board of Directors: None.

5. Other benefits of members of the Board of Directors: None.

6. Transactions between the Company and members of the Board of Directors/related persons: None.

PART IV. OVERALL ASSESSMENT OF THE PERIOD 2022–2026

1. Achievements

During the period 2022–2026, although the Company faced various difficulties relating to finance, the market, raw material prices, livestock diseases and governance matters inherited from previous periods, the Board of Directors and the Executive Management focused resources on maintaining operations, gradually stabilizing production and business activities and improving operating efficiency, achieving the following key results:

- Production and business activities were maintained stably, and revenue gradually recovered following the sharp decline in 2023. In 2025, revenue reached VND 111.69 billion and profit after tax reached VND 8.45 billion, an increase of 123.77% compared with 2024 and 65.75% above the annual plan.
- Business efficiency improved significantly. Profit from production and business activities reached VND 8.47 billion in 2025, an increase of 98.16% compared with 2024, while the profit margin on revenue increased significantly.
- The financial position was gradually strengthened. As at June 30, 2026, equity reached VND 112.03 billion, an increase compared with the end of 2022, while accumulated losses decreased from VND 71.65 billion at the end of 2022 to VND 54.30 billion.
- The Company invested in, constructed and put into operation the Beta-lactam production workshop in accordance with GMP-WHO standards, contributing to improved production capacity and greater product autonomy.
- Corporate governance, receivables, inventories, costs and cash flow controls were gradually strengthened.
- The Company maintained a stable and experienced technical workforce and a long-serving sales team with sales capabilities and market knowledge. These human resources are important factors supporting customer retention, market development and improvement of business results.

- Corporate governance, information disclosure and shareholder relations were gradually maintained in accordance with requirements applicable to public companies and organizations whose shares are registered for trading.

Overall, the 2022–2026 term brought positive changes in production and business activities and the Company's financial position, gradually moving the Company out of a difficult period and creating a foundation for the next term.

2. Outstanding issues and limitations

In addition to the achievements attained, the Company still has certain outstanding issues requiring continued attention and improvement:

- Revenue scale has not fully recovered compared with the beginning of the term; 2025 revenue was approximately 80.6% of the 2022 level.
- Accumulated losses remain significant, amounting to VND 54.30 billion as at June 30, 2026; therefore, the Company has not yet been in a position to distribute profits or dividends to shareholders.
- Business efficiency has not been stable across the years. In the first six months of 2026, although revenue increased significantly, profit after tax decreased by 22.81% year on year and the gross profit margin declined compared with 2025.
- Net cash flows from operating activities were negative VND 6.56 billion in the first six months of 2026, while inventories and trade receivables increased, requiring further improvement in working capital management.
- Certain outstanding issues at the Ho Chi Minh City Branch have not been comprehensively resolved, and operating and business efficiency in the southern region has not met expectations.
- At certain times, management and administration required significant resources to address outstanding issues, limiting the resources available for business expansion and development.
- The veterinary pharmaceutical market remains highly competitive and is affected by disease outbreaks, fluctuations in raw material prices and livestock industry demand; therefore, business results remain subject to various fluctuating factors.

3. Causes

3.1. Objective causes

The Company's operations were affected by economic conditions, market purchasing power, disease outbreaks among livestock, poultry and aquatic species, fluctuations in raw material prices, industry competition, and increasingly stringent requirements concerning standards, quality and management of veterinary medicines.

In addition, the industry is seasonal and highly dependent on livestock production conditions, resulting in fluctuations in revenue and profit between periods.

3.2. Internal causes

The Company entered the term with prolonged financial and governance issues inherited from previous periods. Therefore, during the initial years and much of the term, the Board of Directors and the Executive Management had to devote significant resources to addressing outstanding issues, strengthening operations and restoring production and business capacity at the Head Office.

With respect to the Ho Chi Minh City Branch, certain governance and management issues inherited from previous periods have not been fully resolved and require additional time and

resources for review and remediation. Consequently, the Branch's operating efficiency during the term did not meet expectations.
In addition, capital resources for production, business activities and investment remained limited, while the Company simultaneously had to address accumulated losses, maintain working capital, invest in facilities and develop markets.

4. Lessons learned in governance and management

Based on practical experience during the period 2022–2026, the Board of Directors draws the following key lessons:
- Outstanding governance, financial and organizational issues should be addressed early and comprehensively in order to establish a stable foundation for development.
- Corporate governance must be closely linked to business efficiency, cash flows and capital utilization; the Company should not focus solely on revenue growth but must simultaneously control cost of goods sold, expenses, receivables and inventories.
- Close coordination between the Board of Directors and the Executive Management should be maintained, while responsibilities, authority and accountability of each management level should be clearly defined.
- The Company should leverage the strengths of its experienced technical workforce and capable sales team while continuing to train, attract and retain qualified personnel.
- Investment decisions should be selective and focused, aligned with financial capacity and linked to actual operating efficiency.
- Risk management, receivables, inventory and cash flow management should be carried out regularly, proactively and with clearly assigned responsibilities.
- For affiliated units, operating efficiency and contribution capacity should be fully assessed before further resources are allocated; where performance is unsatisfactory, an appropriate restructuring plan should be developed.

Overall, the period 2022–2026 was a period during which the Company focused on stabilization, addressing outstanding issues and gradual recovery. The achievements during the term, particularly in business efficiency, financial position and production capacity, provide a basis for the Company to enter the 2026–2031 term with the objectives of stable development, improved efficiency and gradual resolution of remaining outstanding issues.

PART V. ORIENTATION FOR THE ACTIVITIES OF THE BOARD OF DIRECTORS FOR THE VIII TERM (2026–2031)

1. Plans and orientation of the Board of Directors

Based on the practical business situation, the Board of Directors has agreed on the following key production and business targets for the VIII term (2026–2031):

Unit: VND billion

No.	Indicator	2026	2027	2028	2029	2030	2031
1	Net revenue	125	135	145	155	165	175
2	Profit after tax	8.5	9.5	10.5	11.5	12.5	13.5

During the next term, the Board of Directors will maintain regular meetings to promptly implement resolutions of the General Meeting of Shareholders and effectively perform corporate governance activities aimed at improving the Company's production and business efficiency.

2. Key objectives of the Company

Given the Company's current circumstances, the Board of Directors will focus on the following specific objectives:

+ **General objectives**
  - Focus on directing the implementation of flexible production and business plans that are responsive to market developments; minimize risks, take advantage of opportunities, maintain stable and efficient production and business activities, and create conditions to increase employees' income.
  - Develop the Company into an enterprise with a strong brand and reputation in the production and trading of veterinary medicines, aquatic medicines and vaccines; maintain stable and sustainable development; gradually expand the market to provinces and cities where the Company has competitive strengths; improve and diversify products and continuously enhance product quality.

+ **Production and business objectives: stable and sustainable development**
  - The Company will manufacture and trade key veterinary pharmaceutical products, including injectable antibiotic solutions, sterile antibiotic powders for injection, oral antibiotic solutions, liquid medicines, antiparasitic medicines, oral powders, vitamins and supplements, and disinfectants.
  - Aquatic medicines: antibiotics, nutritional products, antiparasitic medicines and disinfectants.
  - The Company's products are of high quality and diverse in type, serving animals, pets, livestock and poultry, including medicines for disease prevention and treatment, antiparasitic medicines, health supplements, growth promoters, reproductive regulators and antifungal medicines.
  - To ensure business development, the Company will annually review and strengthen its existing customer base and develop new customers; based on annual sales, it will reassess the standards applicable to first-tier and second-tier distributors in provinces and cities nationwide.
  - Implement multi-channel sales and marketing through online channels, including the Company's website, wholesale and retail distribution systems, and sales through the Company's stores.
  - Maintain effective customer care and establish a technical team to conduct clinical examinations, pathological examinations and technical consultations for farms and livestock producers.
  - Organize regular professional training on the proper use of veterinary medicines for market and sales personnel.
+ **Financial objective:** Build a sound and self-sustaining financial position.
+ **Human resources objective:** Improve the quality of the workforce and ensure adequate staffing and professional competence.

3. Medium- and long-term development strategy

- In the coming period, in addition to focusing on the production and trading of high-quality products to best serve market demand, the Company will promote product sales through market expansion and diversification of customer groups. The Company will also strengthen trading activities, including vaccines for the prevention of diseases in livestock and poultry, thereby strengthening the relationship between the Company and farmers.
- **Production and business strategy:** Expand the scope of operations and gradually establish a solid foundation.
- **Business philosophy:** Take customer service as the purpose of business and business results as the driving force for development.
- **Quality policy strategy:** Continuous innovation and improvement of product quality shall be regarded as the Company's mission.
- **Financial strategy:** Improve the efficiency of using internally generated funds, gradually increase capital to meet production and business requirements in each period, and expand relationships with partners, investors, banks and credit institutions to access external sources of capital.
- **Human resources strategy:** Improve recruitment quality; implement training and management succession planning; appoint and allocate personnel to positions appropriate to their capabilities, professional qualifications and qualities in accordance with regulations and the Company's production and business development requirements; continue improving employee remuneration policies, including salary and bonus schemes, working environment, job positions and collective activities.
- **Corporate culture strategy:** Promote strict compliance by employees with State laws and the Company's internal rules and regulations; ensure employees' rights and benefits and facilitate the effective operation of employee organizations within the Company.

4. Implementation orientation

During the next term, the Company will strive to effectively implement the following development orientations and business strategies:

* **Product development**

- Consolidate, maintain and improve productivity and enhance products manufactured at the GMP-standard veterinary pharmaceutical plant in order to meet market requirements in terms of quality and consumer preferences.
- Continue reviewing, completing and developing the Company's product portfolio, focusing on effective product lines appropriate to changes in disease patterns in Vietnam.
- Increase product value so that the sales system can develop sales and create greater motivation for sales personnel.

* **Marketing**

- Introduce and promote products on the Company's website and develop appropriate sales channels.
- Coordinate with the experimental department to develop and issue product testing procedures to ensure accuracy in testing activities.
- Develop and complete systems of procedures and work standards so that marketing activities become more professional and systematic, supporting the sales system in

developing traditional and modern marketing programs appropriate to market segments and target customers.

- Promote advertising and communications activities and attract potential customers through direct and indirect channels, making product information more accessible to interested customers.
- Develop advertising programs through media channels for strategic product groups.

* **Sales system development and business strategy**

- Complete and develop the sales system in the Northern and Central regions through specific measures, including training in sales skills, communication and product knowledge; developing sales policies appropriate to each market area; and establishing sales targets, income and remuneration policies to motivate the sales team.
- Seek export markets in order to effectively utilize factory capacity, stabilize and increase market share.
- **Intensive growth strategy:** Seek opportunities to improve operating efficiency by expanding products and markets, entering new markets and increasing the market share of existing products in existing markets. In production, the Company will focus on leveraging existing production lines and strengths, expanding scale, improving and gradually modernizing production lines to enhance profitability.

* **Production planning and implementation**

Maximize cost savings to reduce product costs. The Company will continue to improve production planning and implementation through specific measures, including strengthening the production workforce; developing work procedures appropriate to actual conditions and ensuring efficiency; and preparing specific annual, quarterly and monthly plans for raw materials and production throughout the 2026–2031 term to enhance proactiveness in all production-related activities.

* **Finance and financial structure**

+ **Financial management**

- Properly organize the accounting system in accordance with applicable standards and regulations, ensuring that accounting data are fully and accurately reflected; issue regulations and procedures for the circulation of records and supporting documents and ensure accounting in the correct accounting period on a quarterly basis, enabling the Board of Directors to make timely decisions and adjust business plans effectively, while meeting reporting requirements under the Law on Enterprises and the Law on Securities.
- Strictly manage assets, cash flows and inventories.
- Develop appropriate solutions to promote production and business activities and shorten the cash conversion cycle.
- Maximize cost savings in an effective and appropriate manner.
- Properly organize importation, procurement, transportation and inventory stocking based on actual business demand in order to minimize inventory levels; promptly identify and address long-outstanding inventories to avoid capital being tied up.
- Ensure smooth and coordinated production and business processes and minimize idle time of machinery and equipment.

- Provide effective after-sales services to strengthen long-term customer relationships; apply flexible policies for different customer groups, particularly potential customers, in order to create a positive initial impression.
- Improve the efficiency of fixed capital and working capital utilization.
- Develop capital mobilization strategies appropriate to market conditions and the business environment in each period.

+ **Financial structure**

- Properly manage cash and cash equivalents and maintain an appropriate cash reserve; the Board of Directors and the Executive Management shall develop an appropriate capital structure consistent with the Company's production and business characteristics, with the objective of minimizing the cost of capital.
- Complete the management, restructuring and streamlining of the organizational structure and enhance the management capabilities of management personnel through standardized responsibilities and duties.
- Develop training plans to improve professional and managerial qualifications of employees and management personnel who demonstrate responsibility, market awareness and business dynamism; promptly supplement the pool of qualified personnel to meet the Company's requirements for innovation in its business methods.

* **Organizational structure**

- Build and train a strong workforce with appropriate professional qualifications, dynamism and creativity, strong management capabilities and the ability to take initiative in all circumstances.
- Recognize investment in human resources across all departments as a key factor determining work performance.
- Diversify recruitment methods, including centralized training by department, recruitment of highly specialized personnel and engagement of personnel as collaborators.
- Develop remuneration policies to attract and retain capable employees.
- Continue improving the system of internal governance documents to ensure suitability and effectiveness across all Company activities.
- Establish specific standards for evaluating workforce quality.

PART VI. RECOMMENDATIONS AND PROPOSALS

During the 2022–2027 term, the Board of Directors made efforts to perform its governance, direction and supervisory functions in the context of significant difficulties, gradually stabilizing operations and improving production and business efficiency.

Based on the operating results for the period 2022–2026 and the operating orientations for the 2026–2031 term presented in the preceding sections, the Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the following matters:

- Approval of the Report on the operating results of the Board of Directors for the period 2022–2026 and the operating orientations for the 2026–2031 term;
- Approval of the policy to terminate the 2022–2027 term of the Board of Directors prior to its expiration and elect a new Board of Directors for the 2026–2031 term;
- Approval of the production and business plan targets for the 2026–2031 period as presented in Part V of this Report;

- Authorization for the newly elected Board of Directors to continue directing and supervising the Executive Management in implementing the objectives, tasks and solutions set out, and to promptly report to the General Meeting of Shareholders on matters beyond its authority;
- Approval of the policy to downsize/terminate the operations of the Ho Chi Minh City Branch in accordance with the orientation presented in Section 3.2 of Part I, and authorization for the Board of Directors and the Executive Management to develop a specific plan and complete all procedures in accordance with applicable regulations.

The Board of Directors respectfully submits the Report on the activities of the Board of Directors for the period 2022–2026 to the General Meeting of Shareholders for consideration and approval.

Thank you very much.

ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN



NGUYỄN ANH TUẤN

VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

Head Office Address: No. 88 Truong Chinh Street, Kim Lien Ward, Hanoi City
Phone Number : 0243.8691262 | Fax: 0243.8691263
Email: info@vinavetco.com | Website: http://www.vinavetco.com
Business code : **0100102326**

REGULATIONS ON THE ORGANIZATION OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS IN 2026
VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

- *Based on the Enterprise Law No. 59/2020/QH14 dated June 17, 2020;*
- *Pursuant to the Law on Amendments and Supplements to Certain Articles of the Law on Enterprises No. 76/2025/QH15, adopted by the 15th National Assembly of the Socialist Republic of Vietnam at its 9th Session on June 17, 2025, and its guiding documents;*
- *Based on the Securities Law No. 54/2019/QH14 dated November 26, 2019;*
- *Based on Decree 155/2020/ND-CP dated December 31, 2020 and guiding documents;*
- *Based on the Charter of Organization and Operation of Central Vietnam Veterinary Products Joint Stock Company I*

I. GENERAL PROVISIONS

1. scope of application

- This regulation applies to the organization of the Extraordinary General Meeting of Shareholders in 2026 (hereinafter referred to as the "Meeting") of Central Vietnam Veterinary products Joint Stock Company I.

- This regulation specifically stipulates the rights and obligations of Shareholders and participants in the Meeting, conditions, and procedures for conducting the Meeting.

2. Conditions for attending the Congress:

the MeetingShareholders whose names are on the list of Shareholders on the record date for attending the Meeting or authorized representatives of Shareholders.

3. Conditions for conducting the MeetingThe

MeetingThe Meeting is conducted when the number of shareholders/authorized representatives of shareholders attending the meeting represents over 50% of the total voting shares according to the list of shareholders of the Company established on the record date for the list of shareholders attending the Meeting (November 07, 2026).

II. EXECUTIVE BODY AND ASSISTANCE FOR THE MEETING

The Meeting decides on the number and specific list of the Presidium, Secretariat, Shareholder Qualification Inspection Committee, and Inspection Committee.

1. Presidium

The work of the Meeting is managed by the Presidium elected by the Meeting.

The tasks of the Presidium: Conduct the activities of the Meeting according to the program and regulations approved by the Meeting.

Maintaining the Discussion of Shareholders

Maintain the discussion part of the shareholders. Respond to the issues requested by the Congress. Conclude the issues discussed at the Congress, manage the minutes and resolutions of the Congress.

2. Secretariat

-The Secretariat is the department assisting the Chairman's Delegation, working under the direction of the Chairman's Delegation.

-The tasks of the Secretariat:

Record the minutes of the Congress reflecting the contents and issues mentioned by the Congress.Summarize the discussion opinions at the Congress.Draft the minutes and resolutions of the Congress.Receive and transfer to the Chairman's Delegation the questionnaires/comments from shareholders, documents related to the Congress.Collect, preserve, and send to the Company's Board of Directors the feedback forms from shareholders at the Congress.Other tasks as assigned by the Chairman's Delegation.

3. Ballot Counting Committee

The Ballot Counting Committee is the assisting department of the organizing committee and the Chairman's Delegation, working under the direction of the Chairman's Delegation.

The tasks of the Ballot Counting Committee:

Guide and supervise the voting of shareholders at the Congress.Summarize the number of shares voted on each voting content and announce the voting results before the Congress.Other tasks as assigned by the Chairman's Delegation.

III. RIGHTS AND OBLIGATIONS OF SHAREHOLDERS, AUTHORIZED REPRESENTATIVES OF SHAREHOLDERS

Shareholders and authorized representatives of shareholders have the right to attend, discuss, and vote on all issues within the authority and according to the Program of the Congress.

The Chairman's Delegation will publicly announce the Program of the Congress; the opinions of shareholders and authorized representatives of shareholders at the Congress will be discussed publicly.

At the Congress meeting, shareholders and authorized representatives of shareholders will hear the report contents and the contents presented by the Board of Directors mentioned in the Program. conference, discussion and approval of each content in the form of voting cards or ballot papers.

Seriously comply with the working regulations of the conference, respect the results of the conference and the management of the Presidium.

IV. INFORMATION AND SPEECH REGIME IN THE CONFERENCE

The Presidium decides on information about the conference, based on compliance with the law and the interests of the Company.

All shareholders have the right to discuss issues related to the agenda of the conference.

Shareholders who wish to discuss at the conference should register their speech content using the shareholder question/comment form provided by the organizing committee and clearly state the discussion issue, sending it to the secretariat for compilation, reporting to the Presidium to organize the discussion of each issue.

Method of speaking: When expressing opinions, shareholders are invited to the podium at the speaking position designated by the Presidium. Shareholders should speak briefly and focus on the key contents that need to be exchanged, in accordance with the registered speech content and the approved conference agenda. The Presidium will arrange for shareholders to speak in the order of registration, while also addressing shareholders' questions. Issues that have been voted on by the conference will not be discussed again. Issues that shareholders registered to discuss but were not addressed within the discussion time according to the approved conference agenda will be considered by the Board of Directors and answered to shareholders in an appropriate manner after the conference.

The Presidium of the conference has the right to remind or request shareholders to focus on the key content that needs to be expressed to save time and ensure the quality of the discussion.

V. PRINCIPLES OF VOTING ON ISSUES AT THE CONFERENCE

Shareholders will vote on issues at the conference using voting cards and ballot papers.

1. Voting Cards; Ballot Papers

Each shareholder is issued a voting card and a ballot paper printed and stamped by the Company.

+ The voting card will be used to collect votes on the following issues:
  - Approving the personnel of the Presidium, the Secretariat, the ballot counting -committee;
  - Approving the conference agenda, the organization regulations of the conference, the minutes, the resolutions of the conference;
  - Other issues within the authority of the general shareholders' meeting (if any).
  - For the above matters, shareholders are requested to raise their voting cards high, with the front side indicating the number of shares owned or represented facing the Presidium. Shareholders voting "In favor" shall raise their voting cards first, followed by those voting "Against" or having "No opinion," who shall raise their voting cards subsequently.
+ Ballot papers will be used to collect votes on the following matters:
  - Items included in the agenda of the General Meeting of Shareholders;
  - Other matters within the authority of the General Meeting of Shareholders (if any).

2. Voting Procedures

+ The voting contents recorded on the Voting Card will be voted on by shareholders/authorized representatives of shareholders by choosing the voting opinion "Agree," "Disagree," or "Have no opinion" for each voting content (marking the corresponding voting opinion for each voting content).

+ Shareholders shall cast their votes in accordance with the following principles:

- Voting shall commence upon the signal of the Presidium of the meeting or the Head of the Vote Counting Committee and shall end when the last shareholder has cast their vote into the ballot box or after 20 minutes from the start of voting, whichever occurs first.
- Vote counting shall be conducted immediately after the close of voting.
- Invalid ballot papers include:
  - Ballots not in the prescribed form, not issued by the Company, or not bearing the Company's seal;
  - Ballots that are crossed out, corrected, supplemented, or incorrectly filled in;
  - Ballots that are torn or not intact;
  - Ballots containing additional information or symbols;
  - Ballots not marked in any voting option box and/or marked in two (02) or more boxes for each voting item;
  - Ballots without the signature of the shareholder or the shareholder's authorized representative.

+ Voting for each item on the ballot paper is independent; the validity of the vote for one item does not affect the validity of votes for other items.

+ In case a shareholder makes a mistake while filling in the ballot paper, if the ballot has not yet been submitted to the ballot box and the voting time has not expired, the shareholder may directly contact the Head of the Vote Counting Committee to request a replacement ballot to ensure their rights.

+ The voting results shall be announced by the Vote Counting Committee after consolidating the results for all items in the meeting agenda.

VI. CONDITIONS FOR PASSING THE DECISION OF THE GENERAL MEETING1.

1. One (01) common share is equivalent to one (01) voting right.

2. The following issues are approved when the number of shareholders representing at least 65% of the total voting shares of all attending shareholders agrees: Proposal to amend the charter Amendments and supplements to the contents of the Company Charter; and some issues recorded in Article 21 of the Company Charter.

3. Other resolutions are approved when the number of shareholders owning over 50% (fifty percent) of the total voting shares of all attending shareholders agrees (in the case of holding a direct meeting) or over 50% of the total votes of shareholders with voting rights agree (in the

case of collecting opinions from shareholders in writing), except for the cases specified in clauses 3, 4, and 6 of Article 148 of the Enterprise Law.

4. The voting for the election of members of the Board of Directors and Independent Board Members shall be conducted by cumulative voting, whereby each shareholder shall have a total number of votes equal to the number of voting shares owned multiplied by the number of members to be elected to the Board of Directors or the number of Independent Board Members to be elected. Each shareholder may allocate all or part of his/her total votes to one or more candidates.

Candidates elected as members of the Board of Directors or Independent Board Members shall be determined based on the number of votes received, in descending order, starting with the candidate receiving the highest number of votes until the required number of members prescribed in the Company's Charter has been elected.

In the event that two or more candidates receive an equal number of votes for the last available seat on the Board of Directors or among the Independent Board Members, a re-election shall be conducted among the candidates receiving the equal number of votes, or the result shall be determined in accordance with the criteria set out in the Election Regulations.

5. Other issues under the authority of the General Meeting of Shareholders (if any) in accordance with the provisions of the Enterprise Law and the Charter of organization and operation of the Company.

VII. SOME ISSUES AT THE MEETING

1. Use of mobile phones:

To ensure the meeting is conducted seriously, with quality, and achieves good results, the organizing committee requests that distinguished representatives and shareholders turn off their mobile phones or set them to silent mode. If it is necessary to use the phone, please step outside to talk so as not to affect the meeting.

2. Smoking in the hall:

During the meeting, it is requested that attendees do not smoke in the hall to ensure fire safety and a shared living environment. If any attendees wish to smoke, please do so in designated areas suitable for the benefit of the community.

3. Press and media:

No filming, photography, or recording is allowed without the consent of the Presidium during the meeting.
No information may be transmitted outside in any form until the conclusion of the meeting.

VIII. RESPONSIBILITY FOR IMPLEMENTATION

+ The Presidium, the Secretariat, the Shareholder Eligibility Verification Committee, the Ballot Counting Committee, the delegates, and the shareholders/shareholder representatives must comply with the working regulations of the General Meeting.

+ **Sanctions applied:** In the event that any individual violates these Regulations, they will be expelled from the General Meeting by the Presidium.

IX. MINUTES AND RESOLUTIONS OF THE GENERAL MEETING OF SHAREHOLDERS

All main contents of the General Meeting of Shareholders must be recorded by the Secretary of the Meeting in the minutes of the Meeting. The minutes and resolutions of the General Meeting of Shareholders are to be read and approved before the Meeting is adjourned.

Above is the entire Regulation for organizing the Extraordinary General Meeting of Shareholders in 2026 of Central Vietnam Veterinary products Joint Stock Company I.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

ON BEHALF OF THE BOARD OF DIRECTORS
chairman of the board of directors



Nguyen Anh Tuan

VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I (VINAVETCO)

No: 47- 2026/QCB-ĐHĐCĐBT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness

Hanoi, September 12, 2026

REGULATIONS ON THE NOMINATION AND SELF-NOMINATION OF MEMBERS OF THE BOARD OF DIRECTORS FOR THE 2026–2031 TERM

Pursuant to:

- Law on Enterprises No. 59/2020/QH14, adopted by the 14th National Assembly of the Socialist Republic of Vietnam at its 9th session on June 17, 2020, and effective from January 1, 2021;

- The Law on Amendments and Supplements to Certain Articles of the Law on Enterprises No. 76/2025/QH15, adopted by the 15th National Assembly of the Socialist Republic of Vietnam at its 9th Session on June 17, 2025, and its guiding documents;

- The Charter of Central Vietnam Veterinary products Joint Stock Company I, as amended and approved at the 2023 Annual General Meeting of Shareholders on May 6, 2023;

- The Internal Regulations on Corporate Governance of Central Vietnam Veterinary Products Joint Stock Company I, as amended and approved at the 2022 Annual General Meeting of Shareholders on May 28, 2022.

CHAPTER I: GENERAL PROVISIONS

Article 1. Purpose, Scope and Applicable Subjects

1. This Regulation is established to specifically stipulate the principles and procedures for the nomination, self-nomination and election of members of the Board of Directors (BOD) for the 2026–2031 term of Central Vietnam Veterinary products Joint Stock Company I at the 2026 Extraordinary General Meeting of Shareholders, to be held on October 10, 2026.

2. This Regulation applies to all shareholders whose names are included in the list of shareholders entitled to attend the 2026 Extraordinary General Meeting of Shareholders of Central Vietnam Veterinary products Joint Stock Company I, as prepared by the Vietnam Securities Depository and Clearing Corporation (VSDC) based on the record date of October 05, 2026.

Article 2. Rights and Obligations of Shareholders and Authorized Representatives of Shareholders Attending the 2026 Extraordinary General Meeting of Shareholders

1. Each shareholder or authorized representative of a shareholder attending the General Meeting shall receive one (01) Ballot for the election of members of the Board of Directors and one (01) Ballot for the election of independent members of the Board of Directors. Each Ballot shall clearly state the number of shares held by the shareholder or the shareholder's

authorized representative, the corresponding number of voting rights, and the number of votes to be used for the election of members of the Board of Directors.

2. Shareholders and authorized representatives of shareholders are responsible for complying with the conditions, order, procedures and election formalities prescribed in this Regulation, and shall follow the instructions of the Vote Counting Committee and the Chairperson of the General Meeting.

CHAPTER II: REGULATIONS ON THE NOMINATION AND SELF-NOMINATION OF MEMBERS OF THE BOARD OF DIRECTORS FOR THE 2026–2031 TERM

Article 3. Number, Term of Office and Qualifications of Non-Independent Members of the Board of Directors

1. Number of Non-Independent Members of the Board of Directors

The number of non-independent members of the Board of Directors to be elected at the 2026 Extraordinary General Meeting of Shareholders is 02 members.

2. Term of Office of Members of the Board of Directors

The term of office of a member of the Board of Directors shall not **exceed** 05 (five) years and may be re-elected for an unlimited number of terms.

3. Qualifications and Conditions for Members of the Board of Directors

Members of the Board of Directors must satisfy the qualifications and conditions prescribed by the Law on Enterprises, Clause 1, Article 155 of the 2020 Law on Enterprises, the Company's Charter, the Company's Internal Regulations on Corporate Governance, and this Regulation, specifically:

a) Have full civil capacity and not fall within the categories of persons prohibited from managing enterprises as prescribed in Clause 2, Article 17 of the Law on Enterprises.

b) Possess professional qualifications and experience in business administration or in the Company's business fields, industries, or lines of business; being a shareholder of the Company is not required.

c) Be in good health and possess good moral character, honesty, integrity, and a sense of compliance with the law.

d) May concurrently serve as a member of the Board of Directors of another company, but may not concurrently serve as a member of the Board of Directors of more than 05 (five) other companies.

Article 4. Number, Term of Office, Qualifications and Conditions of Independent Members of the Board of Directors *(Pursuant to Clause 2, Article 155 of the 2020 Law on Enterprises)*

1. Number of Independent Members of the Board of Directors

The number of independent members of the Board of Directors to be elected at the 2026 Extraordinary General Meeting of Shareholders is **01 (one) member**.

2. Qualifications and Conditions of Independent Members of the Board of Directors

Independent members of the Board of Directors must satisfy the qualifications and conditions prescribed in Clause 2, Article 155 of the 2020 Law on Enterprises, the Company's Charter, the Company's Internal Regulations on Corporate Governance, and this Regulation, specifically:

a) Must not be a person currently working for the Company, the Company's parent company, or any subsidiary of the Company; and must not have worked for the Company, the Company's parent company, or any subsidiary of the Company for at least 03 (three) consecutive years immediately preceding.

b) Must not be a person currently receiving salary or remuneration from the Company, except for allowances to which members of the Board of Directors are entitled in accordance with regulations.

c) Must not be a person whose spouse, biological father, adoptive father, biological mother, adoptive mother, biological child, adopted child, biological sibling is a major shareholder of the Company, or is a manager of the Company or any subsidiary of the Company.

d) Must not be a person who directly or indirectly owns at least 01% of the total voting shares of the Company.

e) Must not be a person who has previously served as a member of the Board of Directors or a member of the Audit Committee of the Company for at least 05 (five) consecutive years immediately preceding, except where such person has been appointed for 02 (two) consecutive terms.

Article 5. Rights to Nominate and Self-Nominate Candidates for Non-Independent Members and Independent Members of the Board of Directors

1. Shareholders or group of shareholders holding ordinary shares of the Company shall have the right to combine their voting rights to nominate and self-nominate candidates for the Board of Directors in accordance with the Law on Enterprises, the Company's Charter, the Company's Internal Regulations on Corporate Governance, and this Regulation.

2. The number of candidates that a shareholder or group of shareholders is entitled to nominate or self-nominate shall be determined based on the number of members of the Board of Directors to be elected and the percentage of voting ordinary shares held by such shareholder or group of shareholders as of the record date for exercising the right to attend the 2026 Extraordinary General Meeting of Shareholders, which is September 8, 2026.

3. Shareholders or groups of shareholders holding 10% or more of the total voting ordinary shares shall have the right to nominate or self-nominate candidates for the Board of Directors, specifically as follows:

- Shareholders or groups of shareholders holding from 10% to less than 20% of the total voting ordinary shares shall be entitled to nominate or self-nominate up to 01 (one) candidate;

- Shareholders or groups of shareholders holding from 20% to less than 30% of the total voting ordinary shares shall be entitled to nominate or self-nominate up to 02 (two) candidates;

- Shareholders or groups of shareholders holding from 30% to less than 50% of the total voting ordinary shares shall be entitled to nominate or self-nominate up to 03 (three) candidates;

- Shareholders or groups of shareholders holding 50% or more of the total voting ordinary shares shall be entitled to nominate or self-nominate the maximum number of candidates as prescribed by law and the Company's Charter, provided that such number is consistent with the number of Board members to be elected.

4. In the event that the number of candidates nominated and self-nominated is still insufficient to elect the required number of members of the Board of Directors, the incumbent Board of Directors shall be responsible for introducing additional candidates or organizing the nomination in accordance with Clause 5, Article 115 of the Law on Enterprises, the Company's Charter, the Company's Internal Regulations on Corporate Governance, and the Regulations on the Operation of the Board of Directors.

The introduction of additional candidates by the incumbent Board of Directors must be clearly announced and completed before the 2026 Extraordinary General Meeting of Shareholders conducts the voting for the election of members of the Board of Directors, ensuring compliance with applicable laws and relevant regulations.

Article 6. Documents for Nomination and Self-Nomination of Members of the Board of Directors and Independent Members of the Board of Directors

1. The documents for nomination and self-nomination of members of the Board of Directors and independent members of the Board of Directors shall include:

- Application for self-nomination or Nomination Form for a candidate for the Board of Directors or as an independent member of the Board of Directors;

- Curriculum vitae of the candidate, with a photo attached and completed by the candidate;

- Valid copy of the Identity Card/Citizen Identity Card/Passport;

- Valid copy of the Household Registration Book or other documents certifying residence registration in accordance with applicable laws;

- Valid copies of diplomas, degrees and certificates evidencing educational and professional qualifications;

- Power of Attorney and/or Minutes of Meeting of the group of shareholders (in cases where the candidate is nominated or self-nominated by authorization from a group of shareholders).

2. The nomination and self-nomination documents must be submitted to Central Vietnam Veterinary products Joint Stock Company I no later than 16:00 on October 28, 2026, at the following address:

Central Vietnam Veterinary products Joint Stock Company I
Address: No. 88 Truong Chinh Street, Kim Lien Ward, Hanoi.
Tel.: 0243.8691262 / 0988.286.335
Fax: 0243.691.263.

3. In cases where the documents are initially submitted by fax or in scanned form, the candidate/shareholder shall be responsible for submitting the original documents upon registration to attend the General Meeting and before the General Meeting commences.

4. Only nomination and self-nomination dossiers that fully satisfy the prescribed conditions, qualifications and requirements, and candidates who fully satisfy the applicable qualifications and conditions for members of the Board of Directors or independent members of the Board of Directors, shall be included in the List of Candidates announced at the General Meeting of Shareholders.

CHAPTER III: REGULATIONS ON THE ELECTION OF MEMBERS OF THE BOARD OF DIRECTORS AND INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS FOR THE 2026–2031 TERM

Article 7. Selection and Preparation of the List of Candidates

Based on the Nomination Forms and Self-Nomination Forms submitted by shareholders and groups of shareholders, together with the accompanying dossiers of the candidates, the incumbent Board of Directors shall be responsible for reviewing, consolidating and preparing the List of Candidates who fully satisfy the prescribed qualifications and conditions for submission to the 2026 Extraordinary General Meeting of Shareholders for consideration and election of members of the Board of Directors for the 2026–2031 term.

Article 8. Election Principles

The election of members of the Board of Directors and independent members of the Board of Directors shall be conducted in accordance with the following principles:

- Comply with the applicable laws on enterprises and other relevant legal regulations;

- Ensure openness, transparency and democracy, and safeguard the lawful rights and interests of all shareholders;

- The election of members of the Board of Directors shall be conducted by the cumulative voting method in accordance with applicable laws, the Company's Charter and this Regulation;

- The total number of members of the Board of Directors to be elected for the 2026–2031 term is **03 (three) members**, including:

+Number of non-independent members of the Board of Directors: 02 (two) members;
+Number of independent members of the Board of Directors: 01 (one) member.

Article 9. Persons Entitled to Vote

Persons entitled to vote at the General Meeting of Shareholders are shareholders holding voting shares or authorized representatives of shareholders holding voting shares, whose

names are included in the List of Shareholders entitled to attend the 2026 Extraordinary General Meeting of Shareholders, as prepared by the Vietnam Securities Depository and Clearing Corporation (VSDC) based on the record date of **September 8, 2026**, and who are present at the General Meeting.

Article 10. Form and Method of Election

1. The election of members of the Board of Directors and independent members of the Board of Directors shall be conducted directly and by secret ballot at the General Meeting using the cumulative voting method, in accordance with Clause 3, Article 148 of Law No. 59/2020/QH14 on Enterprises.

2. After the General Meeting of Shareholders approves the List of Candidates for non-independent members of the Board of Directors and independent members of the Board of Directors, as well as the election procedures, each shareholder or authorized representative of a shareholder attending the General Meeting shall receive **02 (two) Ballots**, including:

+ 01 (one) Ballot for the election of non-independent members of the Board of Directors;
+ 01 (one) Ballot for the election of independent members of the Board of Directors.

Shareholders or their authorized representatives are responsible for checking the information stated on the Ballots. In case of any inaccurate information or errors, they must immediately notify the Organizing Committee for verification and handling.

3. Each Ballot shall clearly state: the list of candidates arranged in alphabetical order **A, B, C...**; shareholder code; number of shares owned or represented under authorization; total number of voting rights and total number of votes available for the election. Each Ballot shall bear the Company's overlapping seal.

4. Number of Votes Available for Election

Each shareholder or authorized representative of a shareholder shall have a total number of votes equal to the total number of voting shares owned or represented under authorization multiplied by the number of members to be elected, specifically:

a) Election of Non-Independent Members of the Board of Directors

Total number of votes = Total number of voting shares × Number of non-independent members of the Board of Directors to be elected

The number of non-independent members of the Board of Directors to be elected is 02 (two) members.

b) Election of Independent Members of the Board of Directors

Total number of votes = Total number of voting shares × Number of independent members of the Board of Directors to be elected

The number of independent members of the Board of Directors to be elected is 01 (one) member.

c) Method of Allocating Voting Ballots

Shareholders or their authorized representatives may allocate all or part of their total votes to one (01) or more candidates. The total number of votes allocated to the candidates must not exceed the total number of votes that the shareholder or authorized representative is entitled to use.

Article 11. Vote Counting Committee

1. The Vote Counting Committee shall be nominated by the Chairperson of the General Meeting and approved by the 2026 Extraordinary General Meeting of Shareholders.

2. Members of the Vote Counting Committee must not be included in the List of candidates nominated or self-nominated for membership of the Board of Directors or as independent members of the Board of Directors.

3. The Vote Counting Committee shall be responsible for ensuring **integrity, objectivity, accuracy and confidentiality** throughout the election and vote-counting process.

4. The Vote Counting Committee shall have the following duties:

- Review and announce the List of Candidates for non-independent members of the Board of Directors and the List of Candidates for independent members of the Board of Directors;

- Submit the Election Regulations and relevant election contents and procedures to the General Meeting of Shareholders for approval;

- Guide shareholders and their authorized representatives on how to complete and cast their ballots;

- Distribute and collect Ballots;

- Count the votes, prepare the Minutes of Vote Counting, and announce the vote-counting results to the 2026 Extraordinary General Meeting of Shareholders;

- Coordinate with the Chairperson of the General Meeting to consider and resolve complaints and recommendations concerning candidates and election results (if any), and report matters falling within the authority of the General Meeting of Shareholders to the General Meeting for decision;

- The Vote Counting Committee shall be responsible before the law and the 2026 Extraordinary General Meeting of Shareholders for proper compliance with this Regulation and for the accuracy and integrity of the vote-counting results.

Article 12. Voting and Vote Counting

1. Voting shall commence after the Vote Counting Committee has completed the distribution of the Ballots and shall end when the last shareholder or authorized representative of a shareholder has completed casting their Ballot into the ballot box.

2. Before voting begins, the Vote Counting Committee shall inspect the ballot box in the presence of the shareholders attending the General Meeting and ensure that the ballot box is empty and contains no Ballots.

Vote counting shall be conducted by the Vote Counting Committee at the designated vote-counting area immediately after voting ends.

3. Upon completion of the vote counting, the Vote Counting Committee shall prepare the Minutes of Vote Counting, fully recording the vote-counting results in accordance with applicable regulations. The Head of the Vote Counting Committee shall announce the vote-counting results to the 2026 Extraordinary General Meeting of Shareholders.

Article 13. Principles for Determining Election Results

1. The election results for non-independent members of the Board of Directors and independent members of the Board of Directors shall be determined separately for each category of members, based on the number of votes received by each candidate, in descending order, starting with the candidate receiving the highest number of votes until the required number of non-independent members of the Board of Directors and independent members of the Board of Directors has been elected.

2. In the event that 02 (two) or more candidates receive an equal number of votes for the last available position among the required number of members to be elected, priority shall be given to the candidate holding a larger number of shares.

If the candidates hold an equal number of shares, the General Meeting of Shareholders shall conduct a re-election among the candidates receiving an equal number of votes to determine the successful candidate(s).

Article 14. Preparation and Announcement of the Minutes of Vote Counting

Upon completion of the vote counting, the Vote Counting Committee shall prepare the Minutes of Vote Counting. The Minutes of Vote Counting shall include the following principal contents:

- The time and location of the vote counting and preparation of the Minutes of Vote Counting;

- The total number of Ballots distributed, the total number of Ballots collected, and the number of Ballots not collected;

- The total number of valid Ballots and invalid Ballots;

- The election results for non-independent members of the Board of Directors and independent members of the Board of Directors;

- Other matters related to the vote-counting process (if any);

- Signatures of the members of the Vote Counting Committee.

The Minutes of Vote Counting shall be announced by the Vote Counting Committee to the 2026 Extraordinary General Meeting of Shareholders.

Article 15. Right to Question and Lodge Complaints

Shareholders or their authorized representatives attending the General Meeting shall have the right to raise questions, make recommendations or lodge complaints regarding the nomination, self-nomination, election and vote-counting processes.

The Chairperson of the General Meeting and the Vote Counting Committee shall be responsible for providing explanations and clarifications regarding matters raised by shareholders or their authorized representatives within their respective authority. Any questions, recommendations, complaints and the corresponding explanations and handling thereof (if any) shall be recorded in the Minutes of the 2026 Extraordinary General Meeting of Shareholders.

Article 16. Effectiveness of the Regulations

These Regulations shall take effect from the time they are approved by the 2026 Extraordinary General Meeting of Shareholders and shall apply solely to the nomination, self-nomination and election of non-independent members of the Board of Directors and independent members of the Board of Directors for the 2026–2031 term at the 2026 Extraordinary General Meeting of Shareholders of Central Vietnam Veterinary products Joint Stock Company I

Recipients:

- General Meeting of Shareholders;
- Board of Directors and Audit Committee;
- Filed with the Board of Directors.

ON BEHALF OF THE GENERAL MEETING OF SHAREHOLDERS
CHAIRPERSON

CÔNG TY CỔ PHẦN THUỐC THÚ Y TRUNG ƯƠNG I

Nguyen Anh Tuan

APPENDIX

GUIDELINES FOR THE ELECTION OF NON-INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS AND INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS FOR THE 2026–2031 TERM

(Cumulative Voting Method)

1. Types of Ballots

There are 02 (two) types of Ballots**, including:**

- Ballot for the election of non-independent members of the Board of Directors;

- Ballot for the election of independent members of the Board of Directors.

2. Voting Method

Shareholders or their authorized representatives shall cast the Ballot for the election of non-independent members of the Board of Directors and the Ballot for the election of independent members of the Board of Directors into the ballot box in accordance with the instructions of the Vote Counting Committee.

3. How to Complete the Ballot

Each shareholder or authorized representative of a shareholder shall have a total number of votes determined by the total number of voting shares owned or represented under authorization, multiplied by the number of Board members to be elected.

Specifically:

+ For the election of non-independent members of the Board of Directors:

Total number of votes = Total number of voting shares × 02 (two) members

+ For the election of independent members of the Board of Directors:

Total number of votes = Total number of voting shares × 01 (one) member

Shareholders or their authorized representatives may allocate their total votes to one or more candidates at their discretion, provided that:

+ The total number of votes allocated to the candidates does not exceed the total number of votes that the shareholder or authorized representative is entitled to use;

+ For the election of non-independent members of the Board of Directors, a shareholder may select a maximum of 02 (two) candidates from the List of Candidates;

+ For the election of an independent member of the Board of Directors, a shareholder may select a maximum of 01 (one) candidate from the List of Candidates.

A shareholder may allocate all of their votes to one candidate or distribute their votes among several candidates in accordance with the cumulative voting method.

4. Invalid Ballots

Ballots shall be deemed invalid if they fall into any of the following cases:

- The Ballot is not issued by Central Veterinary products Joint Stock Company I and/or does not bear the Company's seal as prescribed;

- The Ballot has been erased, altered or supplemented in a manner inconsistent with the prescribed requirements; in case a shareholder makes an error and wishes to replace the Ballot, the shareholder must contact the Vote Counting Committee to obtain a new Ballot in accordance with the regulations;

- The Ballot includes an additional candidate's name or a candidate's name that is not included in the List of Candidates approved by the General Meeting of Shareholders;

- The total number of votes allocated to the candidates exceeds the total number of votes that the shareholder or authorized representative is entitled to use;

- The Ballot does not bear the signature and/or full name of the shareholder or the shareholder's authorized representative as prescribed;

- The Ballot selects a number of candidates exceeding the number of candidates that the shareholder is entitled to select under the regulations;

- The Ballot does not indicate any votes for any candidate;

- Other cases in which the shareholder's intention regarding the selection of candidates cannot be determined in accordance with these Regulations.

Example of the Election of Non-Independent Members of the Board of Directors

a) Election of Non-Independent Members of the Board of Directors

Assume that the General Meeting of Shareholders approves the election of 02 (two) non-independent members of the Board of Directors for the 2026–2031 term from a total of 03 (three) candidates.

Shareholder Nguyen Van A owns and/or represents under authorization 1,000 voting shares.

The total number of votes of shareholder Nguyen Van A is: 1,000 × 2 = 2,000 votes

Shareholder Nguyen Van A may select a maximum of **02 (two)** candidates out of the total 03 candidates. The total number of votes allocated to the candidates must not exceed 2,000 votes.

Shareholder Nguyen Van A may allocate the votes in the following ways:

Case 1: Equal allocation of votes to 02 candidates

Shareholder Nguyen Van A allocates the 2,000 votes equally to 02 candidates, with each candidate receiving 1,000 votes:

No.	NAME OF CANDIDATE	CUMULATIVE VOTES	NUMBER OF VOTES
1	Candidate 1	☒	1.000
2	Candidate 2		
3	Candidate 3	☒	1.000

Case 2: Allocation of all votes to 01 candidate

Shareholder Nguyen Van A allocates all 2,000 votes to 01 candidate:

No.	NAME OF CANDIDATE	CUMULATIVE VOTES	NUMBER OF VOTES
1	Candidate 1		0
2	Candidate 2	☒	2.000
3	Candidate 3		0

Case 3: Unequal allocation of votes to 02 candidates

Shareholder Nguyen Van A allocates the 2,000 votes to 02 candidates, with Candidate 1 receiving 1,500 votes and Candidate 3 receiving 500 votes:

No.	NAME OF CANDIDATE	CUMULATIVE VOTES	NUMBER OF VOTES
1	Candidate 1	☒	1.500
2	Candidate 2		0
3	Candidate 3	☒	500

b) Election of Independent Members of the Board of Directors

Assume that the General Meeting of Shareholders approves the election of 01 (one) independent member of the Board of Directors for the 2026–2031 term from a total of 02 (two) candidates.

Shareholder Nguyen Van A owns and/or represents under authorization 1,000 voting shares.

The total number of votes of shareholder Nguyen Van A is: 1,000 × 1 = 1,000 votes

As only 01 (one) independent member of the Board of Directors is to be elected, shareholder Nguyen Van A may select only 01 (one) candidate from the total of 02 candidates and may allocate all 1,000 votes to the selected candidate.

Case 1: Allocation of all votes to 01 candidate

No.	NAME OF CANDIDATE	CUMULATIVE VOTES	NUMBER OF VOTES
1	Candidate 1		0
2	Candidate 2	☒	1.000

CÔNG TY CỔ PHẦN THUỐC THÚ Y TRUNG ƯƠNG I
Digitally signed by CÔNG TY CỔ PHẦN THUỐC THÚ Y TRUNG ƯƠNG I
DN: C=VN, S=Hà Nội, CN=CÔNG TY CỔ PHẦN THUỐC THÚ Y TRUNG ƯƠNG I, OID.0.9.2342.19200300.100.1.1=MST:0100102326
Reason: I am the author of this document
Location:
Date: 2026.11.07 18:33:11+07'00'
Foxit PDF Reader Version: 2025.1.0